<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2019-25-2-143-157</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-1824</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Коморбидные инсомния и артериальная гипертензия: патогенетические модели и перспективные биомаркеры</article-title><trans-title-group xml:lang="en"><trans-title>Comorbid insomnia and arterial hypertension: pathogenetic models and promising biomarkers</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фильченко</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Filchenko</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>клинический ординатор кафедры неврологии им. акад. С. Н. Давиденкова</p><p>Санкт-Петербург, Россия</p></bio><bio xml:lang="en"><p>Clinical resident, Department of neurology named after acad. S. N. Davidenkov</p><p> </p></bio><email xlink:type="simple">iriina6994@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коростовцева</surname><given-names>Л. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Korostovtseva</surname><given-names>L. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, научный сотрудник группы по сомнологии НИЛ артериальной гипертензии Института сердца и сосудов, доцент кафедры кардиологии</p><p>ул. Аккуратова, д. 2, Санкт-Петербург, Россия, 197341.Тел.: +7(812) 702–37–33.</p></bio><bio xml:lang="en"><p>MD, PhD, Researcher, Somnology Laboratory, Research Department for Hypertension, Institute of the Heart and Vessels, Associate Professor, Cardiology Department</p><p>2 Akkuratov street, St Petersburg, 197341 Russia</p></bio><email xlink:type="simple">korostovtseva_ls@almazovcentre.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терещенко</surname><given-names>Н. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Tereshchenko</surname><given-names>N. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>лаборант-исследователь лаборатории сравнительной сомнологии и нейроэндокринологии</p><p>Санкт-Петербург, Россия</p></bio><bio xml:lang="en"><p>Laboratory assistant, Laboratory of comparative somnology and neuroendocrinology</p><p>St Petersburg, Russia</p></bio><email xlink:type="simple">nickolaitereshenko@yandex.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Свиряев</surname><given-names>Ю. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Sviryaev</surname><given-names>Y. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, руководитель группы по сомнологии НИЛ артериальной гипертензии Института сердца и сосудов</p><p>Санкт-Петербург, Россия</p></bio><bio xml:lang="en"><p>MD, PhD, DSc, Head, Somnology Laboratory, Research Department for Hypertension, Institute of the Heart and Vessels</p><p>St Petersburg, Russia</p></bio><email xlink:type="simple">sviryaev_yuv@almazovcentre.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вознюк</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Voznjouk</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заместитель директора по научной работе</p><p>Санкт-Петербург, Россия</p></bio><bio xml:lang="en"><p>MD, PhD, DSc, Prof, Deputy Director for Science</p><p>St Petersburg, Russia</p></bio><email xlink:type="simple">voznjouk@yandex.ru</email><xref ref-type="aff" rid="aff-5"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации,&#13;
Федеральное государственное бюджетное учреждение науки «Институт эволюционной физиологии и биохимии им. И. М. Сеченова»  Российской академии наук,&#13;
Федеральное государственное бюджетное образовательное учреждение высшего образования «Северо-Западный государственный медицинский университет им. И. И. Мечникова» Министерства здравоохранения Российской Федерации</aff><aff xml:lang="en">Almazov National Medical Research Centre,&#13;
Sechenov Institute of Evolutionary Physiology&#13;
and Biochemistry,&#13;
North-Western State Medical University named&#13;
after I. I. Mechnikov</aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации<country>Россия</country></aff><aff xml:lang="en">Almazov National Medical Research Centre<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">Федеральное государственное бюджетное учреждение науки «Институт эволюционной физиологии и биохимии им. И. М. Сеченова» Российской академии наук</aff><aff xml:lang="en">Sechenov Institute of Evolutionary Physiology and Biochemistry</aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени В. А. Алмазова» Министерства здравоохранения Российской Федерации,&#13;
Федеральное государственное бюджетное учреждение науки «Институт эволюционной физиологии и биохимии им. И. М. Сеченова» Российской академии наук</aff><aff xml:lang="en">Almazov National Medical Research Centre,&#13;
Sechenov Institute of Evolutionary Physiology&#13;
and Biochemistry</aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru">Государственное бюджетное учреждение «Санкт-Петербургский научно-исследовательский институт скорой помощи имени И. И. Джанелидзе»</aff><aff xml:lang="en">Saint-Petersburg I. I. Dzhanelidze Research Institute of Emergency Medicine</aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>24</day><month>05</month><year>2019</year></pub-date><volume>25</volume><issue>2</issue><fpage>143</fpage><lpage>157</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Фильченко И.А., Коростовцева Л.С., Терещенко Н.М., Свиряев Ю.В., Вознюк И.А., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Фильченко И.А., Коростовцева Л.С., Терещенко Н.М., Свиряев Ю.В., Вознюк И.А.</copyright-holder><copyright-holder xml:lang="en">Filchenko I.A., Korostovtseva L.S., Tereshchenko N.M., Sviryaev Y.V., Voznjouk I.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/1824">https://htn.almazovcentre.ru/jour/article/view/1824</self-uri><abstract><p>В данной обзорной статье описаны основные механизмы возникновения и поддержания коморбидных инсомнии и артериальной гипертензии с учетом актуальных патогенетических сценариев инсомнии, включающих концепцию симпатической активации, нейробиологическую модель инсомнии и трехфакторную модель. Результаты единичных клинических исследований свидетельствуют о взаимосвязи уровней артериального давления с гиперактивацией центральной нервной системы во время сна, характеризуемой по электроэнцефалографической активности в диапазоне β-спектра, и с показателями латентности сна. Тем не менее биологически активные вещества, опосредующие так называемое «нейрогенное воспаление», также играют значимую роль в поддержании гомеостаза при воздействии эндогенных и экзогенных стрессорных факторов. Функции интерлейкина‑6, гамма-аминомасляной кислоты, субстанции Р, мелатонина, серотонина и орексина в норме и в патологии позволяют высказать предположение об их участии в механизмах реализации взаимосвязи инсомнии и артериальной гипертензии. Подчеркивается важность трактовки инсомнии в качестве отдельной нозологической единицы, сопутствующей артериальной гипертензии, и актуальность исследований молекулярных механизмов взаимосвязи инсомнии и артериальной гипертензии с целью определения перспективных терапевтических мишеней и прогностических маркеров при конкретном патогенетическом сценарии.</p></abstract><trans-abstract xml:lang="en"><p>The review describes the major mechanisms for the initiation and maintenance of comorbid insomnia and arterial hypertension based on the relevant pathogenetic scenarios of insomnia such as the concept of sympathetic activation, the neurobiological model of insomnia, and stress-diathesis model (or 3-P model). The clinical data are lacking, and available clinical studies indicate the association between blood pressure levels and the hyperactivation of the central nervous system during sleep, characterized by electroencephalographic β-activity, and with sleep latency. However, biologically active substances involved in “neurogenic inflammation” also play a significant role in homeostasis maintenance following the exposure to endogenous and exogenous stress factors. The functions of interleukin-6, gamma-aminobutyric acid, substance P, melatonin, serotonin and orexin in normal and pathological conditions indicate their contribution to the development of comorbid insomnia and hypertension. We emphasize the role of insomnia as a separate nosological unit, comorbid with hypertension, as well as the importance of research of molecular mechanisms underlying the association between insomnia and arterial hypertension aimed at identification of therapeutic targets and prognostic markers.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инсомния</kwd><kwd>бессонница</kwd><kwd>артериальная гипертензия</kwd><kwd>биомаркер</kwd><kwd>нейрогенное воспаление</kwd></kwd-group><kwd-group xml:lang="en"><kwd>insomnia</kwd><kwd>sleeplessness</kwd><kwd>hypertension</kwd><kwd>biomarker</kwd><kwd>neurogenic inflammation</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Работа выполнена при поддержке гранта Российского научного фонда, проект № 17–75–10099.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zucconi M, Ferri R. Assessment of sleep disorders and diagnostic procedures. European Sleep Research Society. 2014.</mixed-citation><mixed-citation xml:lang="en">Zucconi M, Ferri R. Assessment of sleep disorders and diagnostic procedures. European Sleep Research Society. 2014.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Morin CM, Benca R. Chronic insomnia. The Lancet. 2012;379(9821):1129–41. doi:10.1016/S0140-6736(11)60750-2</mixed-citation><mixed-citation xml:lang="en">Morin CM, Benca R. Chronic insomnia. The Lancet. 2012;379(9821):1129–41. doi:10.1016/S0140-6736(11)60750-2</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. Chest. 2015;147(4):1179–92. doi:10.1378/chest.14-1617</mixed-citation><mixed-citation xml:lang="en">Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. Chest. 2015;147(4):1179–92. doi:10.1378/chest.14-1617</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Buysse DJ. Insomnia. J Am Med Assoc 2012;309(7):706–16. doi:10.1001/jama.2013.193.Insomnia</mixed-citation><mixed-citation xml:lang="en">Buysse DJ. Insomnia. J Am Med Assoc 2012;309(7):706–16. doi:10.1001/jama.2013.193.Insomnia</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Buysse DJ, Germain A, Hall M, Monk TH, Nofzinger EA. A neurobiological model of insomnia. Drug Discovery Today: Disease Models. 2011;8(4):129–137. doi:10.1016/j.ddmod.2011.07.002.A</mixed-citation><mixed-citation xml:lang="en">Buysse DJ, Germain A, Hall M, Monk TH, Nofzinger EA. A neurobiological model of insomnia. Drug Discovery Today: Disease Models. 2011;8(4):129–137. doi:10.1016/j.ddmod.2011.07.002.A</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Walsh JK, Coulouvrat C, Hajak G, Lakoma MD, Petukhova M, Roth T, et al. Nighttime insomnia symptoms and perceived health in the america insomnia survey (AIS). Sleep. 2011;34(8):997–1011. doi:10.5665/SLEEP.1150</mixed-citation><mixed-citation xml:lang="en">Walsh JK, Coulouvrat C, Hajak G, Lakoma MD, Petukhova M, Roth T, et al. Nighttime insomnia symptoms and perceived health in the america insomnia survey (AIS). Sleep. 2011;34(8):997–1011. doi:10.5665/SLEEP.1150</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Winkelman JW. Insomnia disorder. New England Journal of Medicine. 2015;373(15):1437–44. doi:10.1056/NEJMcp1412740</mixed-citation><mixed-citation xml:lang="en">Winkelman JW. Insomnia disorder. New England Journal of Medicine. 2015;373(15):1437–44. doi:10.1056/NEJMcp1412740</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Javaheri S, Redline S. Insomnia and risk of cardiovascular disease. Chest. 2017;152(2):435–44. doi:10.1016/j.chest.2017.01.026</mixed-citation><mixed-citation xml:lang="en">Javaheri S, Redline S. Insomnia and risk of cardiovascular disease. Chest. 2017;152(2):435–44. doi:10.1016/j.chest.2017.01.026</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jarrin DC, Alvaro PK, Bouchard MA, Jarrin SD, Drake CL, Morin CM. Insomnia and hypertension: A systematic review. Sleep Medicine Reviews. 2018;41:3–38. doi:10.1016/j.smrv.2018.02.003</mixed-citation><mixed-citation xml:lang="en">Jarrin DC, Alvaro PK, Bouchard MA, Jarrin SD, Drake CL, Morin CM. Insomnia and hypertension: A systematic review. Sleep Medicine Reviews. 2018;41:3–38. doi:10.1016/j.smrv.2018.02.003</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zhan Y, Chen R, Zhang F, Wang J, Sun Y, Ding R, et al. Insomnia and its association with hypertension in a communitybased population in China: A cross-sectional study. Heart Asia. 2014;6(1):88–93. doi:10.1136/heartasia‑2013-010440</mixed-citation><mixed-citation xml:lang="en">Zhan Y, Chen R, Zhang F, Wang J, Sun Y, Ding R, et al. Insomnia and its association with hypertension in a communitybased population in China: A cross-sectional study. Heart Asia. 2014;6(1):88–93. doi:10.1136/heartasia‑2013-010440</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Budhiraja R, Roth T, Hudgel DW, Budhiraja P, Drake CL. Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep. 2011;34(7):859–67. doi:10.5665/sleep.1114</mixed-citation><mixed-citation xml:lang="en">Budhiraja R, Roth T, Hudgel DW, Budhiraja P, Drake CL. Prevalence and polysomnographic correlates of insomnia comorbid with medical disorders. Sleep. 2011;34(7):859–67. doi:10.5665/sleep.1114</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lin CL, Liu TC, Lin FH, Chung CH, Chien WC. Association between sleep disorders and hypertension in Taiwan: A nationwide population-based retrospective cohort study. J Hum Hypertens. 2016;31(3):220–4. doi:10.1038/jhh.2016.55</mixed-citation><mixed-citation xml:lang="en">Lin CL, Liu TC, Lin FH, Chung CH, Chien WC. Association between sleep disorders and hypertension in Taiwan: A nationwide population-based retrospective cohort study. J Hum Hypertens. 2016;31(3):220–4. doi:10.1038/jhh.2016.55</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bathgate CJ, Edinger JD, Wyatt JK, Krystal AD. Objective but not subjective short sleep duration associated with increased risk for hypertension in individuals with insomnia. Sleep. 2016;39(5): 1037–45. doi:10.5665/sleep.5748</mixed-citation><mixed-citation xml:lang="en">Bathgate CJ, Edinger JD, Wyatt JK, Krystal AD. Objective but not subjective short sleep duration associated with increased risk for hypertension in individuals with insomnia. Sleep. 2016;39(5): 1037–45. doi:10.5665/sleep.5748</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491–7. doi:10.1093/sleep/32.4.491</mixed-citation><mixed-citation xml:lang="en">Vgontzas AN, Liao D, Bixler EO, Chrousos GP, Vela-Bueno A. Insomnia with objective short sleep duration is associated with a high risk for hypertension. Sleep. 2009;32(4):491–7. doi:10.1093/sleep/32.4.491</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez-Mendoza J, Vgontzas AN, Liao D, Shaffer ML, Vela-Bueno A, Basta M, et al. Insomnia with objective short sleep duration and incident hypertension: The Penn State Cohort. Hypertension. 2012;60(4):929–35. doi:10.1161/HYPERTENSIONAHA.112.193268</mixed-citation><mixed-citation xml:lang="en">Fernandez-Mendoza J, Vgontzas AN, Liao D, Shaffer ML, Vela-Bueno A, Basta M, et al. Insomnia with objective short sleep duration and incident hypertension: The Penn State Cohort. Hypertension. 2012;60(4):929–35. doi:10.1161/HYPERTENSIONAHA.112.193268</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ramos AR, Weng J, Wallace DM, Petrov MR, Wohlgemuth WK, Sotres-Alvarez D, et al. Sleep patterns and hypertension using actigraphy in the Hispanic Community Health Study/Study of Latinos. Chest. 2018;153(1):87–93. doi:10.1016/jchest.2017.09.028</mixed-citation><mixed-citation xml:lang="en">Ramos AR, Weng J, Wallace DM, Petrov MR, Wohlgemuth WK, Sotres-Alvarez D, et al. Sleep patterns and hypertension using actigraphy in the Hispanic Community Health Study/Study of Latinos. Chest. 2018;153(1):87–93. doi:10.1016/jchest.2017.09.028</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Vozoris NT. Insomnia symptom frequency and hypertension risk. J Clin Psychiatry. 2014;75(06):616–23. doi:10.4088/jcp.13m08818</mixed-citation><mixed-citation xml:lang="en">Vozoris NT. Insomnia symptom frequency and hypertension risk. J Clin Psychiatry. 2014;75(06):616–23. doi:10.4088/jcp.13m08818</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Uka MS, Oshida KY, Ugimori HS. Persistent insomnia is a predictor of hypertension in Japanese male workers. J Occup Health. 2003;45:344–50.</mixed-citation><mixed-citation xml:lang="en">Uka MS, Oshida KY, Ugimori HS. Persistent insomnia is a predictor of hypertension in Japanese male workers. J Occup Health. 2003;45:344–50.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Phillips B, Bůžková P, Enright P. Insomnia did not predict incident hypertension in older adults in the Cardiovascular Health Study. Sleep. 2009;32(1):65–72. doi:10.5665/sleep/32.1.65</mixed-citation><mixed-citation xml:lang="en">Phillips B, Bůžková P, Enright P. Insomnia did not predict incident hypertension in older adults in the Cardiovascular Health Study. Sleep. 2009;32(1):65–72. doi:10.5665/sleep/32.1.65</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sforza E, Saint Martin M, Barthelemy JC, Roche F. Association of self-reported sleep and hypertension in noninsomniac elderly subjects. J Clin Sleep Med. 2014;10(9):955–71. doi:10.5664/jcsm.4026</mixed-citation><mixed-citation xml:lang="en">Sforza E, Saint Martin M, Barthelemy JC, Roche F. Association of self-reported sleep and hypertension in noninsomniac elderly subjects. J Clin Sleep Med. 2014;10(9):955–71. doi:10.5664/jcsm.4026</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas SJ, Calhoun D. Sleep, insomnia, and hypertension: current findings and future directions. J Am Soc Hypertens. 2017;11(2):122–9. doi:10.1016/j.jash.2016.11.008</mixed-citation><mixed-citation xml:lang="en">Thomas SJ, Calhoun D. Sleep, insomnia, and hypertension: current findings and future directions. J Am Soc Hypertens. 2017;11(2):122–9. doi:10.1016/j.jash.2016.11.008</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Castro-Diehl C, Diez Roux A V., Redline S, Seeman T, McKinley P, Sloan R, et al. Sleep duration and quality in relation to autonomic nervous system measures: the multi-ethnic study of atherosclerosis (MESA). Sleep. 2016;39(11):1927–40. doi:10.5665/sleep.6218</mixed-citation><mixed-citation xml:lang="en">Castro-Diehl C, Diez Roux A V., Redline S, Seeman T, McKinley P, Sloan R, et al. Sleep duration and quality in relation to autonomic nervous system measures: the multi-ethnic study of atherosclerosis (MESA). Sleep. 2016;39(11):1927–40. doi:10.5665/sleep.6218</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Yamashita A, Hamada A, Suhara Y, Kawabe R, Yanase M, Kuzumaki N, et al. Astrocytic activation in the anterior cingulate cortex is critical for sleep disorder under neuropathic pain. Synapse. 2014;68(6):235–47. doi:10.1002/syn.21733</mixed-citation><mixed-citation xml:lang="en">Yamashita A, Hamada A, Suhara Y, Kawabe R, Yanase M, Kuzumaki N, et al. Astrocytic activation in the anterior cingulate cortex is critical for sleep disorder under neuropathic pain. Synapse. 2014;68(6):235–47. doi:10.1002/syn.21733</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Guadagni V, Burles F, Ferrara M, Iaria G. Sleep quality and its association with the insular cortex in emotional empathy. Eur J Neurosci. 2018;48(6):2288–300. doi:10.1111/ejn.14124</mixed-citation><mixed-citation xml:lang="en">Guadagni V, Burles F, Ferrara M, Iaria G. Sleep quality and its association with the insular cortex in emotional empathy. Eur J Neurosci. 2018;48(6):2288–300. doi:10.1111/ejn.14124</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ono D, Yamanaka A. Hypothalamic regulation of the sleep/wake cycle. Neurosci Res. 2017;118:74–81. doi:10.1016/j.neures.2017.03.013</mixed-citation><mixed-citation xml:lang="en">Ono D, Yamanaka A. Hypothalamic regulation of the sleep/wake cycle. Neurosci Res. 2017;118:74–81. doi:10.1016/j.neures.2017.03.013</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Coote JH, Spyer KM. Central control of autonomic function. Brain and Neuroscience Advances. 2018;2:239821281881201. doi:10. 1177/2398212818812012</mixed-citation><mixed-citation xml:lang="en">Coote JH, Spyer KM. Central control of autonomic function. Brain and Neuroscience Advances. 2018;2:239821281881201. doi:10. 1177/2398212818812012</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Li Y, Vgontzas AN, Fernandez-Mendoza J, Bixler EO, Sun Y, Zhou J, et al. Insomnia with physiological hyperarousal is associated with hypertension. Hypertension. 2015;65:644–50. doi:10.1161/HYPERTENSIONAHA.114.04604</mixed-citation><mixed-citation xml:lang="en">Li Y, Vgontzas AN, Fernandez-Mendoza J, Bixler EO, Sun Y, Zhou J, et al. Insomnia with physiological hyperarousal is associated with hypertension. Hypertension. 2015;65:644–50. doi:10.1161/HYPERTENSIONAHA.114.04604</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):9–15. doi:10.1016/j.smrv.2009.05.002</mixed-citation><mixed-citation xml:lang="en">Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):9–15. doi:10.1016/j.smrv.2009.05.002</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Chen GH, Xia L, Wang F, Li XW, Jiao CA. Patients with chronic insomnia have selective impairments in memory that are modulated by cortisol. Psychophysiology. 2016;53(10):1567–76. doi:10.1111/psyp.12700</mixed-citation><mixed-citation xml:lang="en">Chen GH, Xia L, Wang F, Li XW, Jiao CA. Patients with chronic insomnia have selective impairments in memory that are modulated by cortisol. Psychophysiology. 2016;53(10):1567–76. doi:10.1111/psyp.12700</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">DiBona GF. Sympathetic nervous system, diabetes, and hypertension. Hypertension. 2013;61:556–60. doi:10.1081/CEH‑100001196</mixed-citation><mixed-citation xml:lang="en">DiBona GF. Sympathetic nervous system, diabetes, and hypertension. Hypertension. 2013;61:556–60. doi:10.1081/CEH‑100001196</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Lanfranchi PA, Pennestri MH, Fradette L, Dumont M, Morin CM, Montplaisir J. Nighttime blood pressure in normotensive subjects with chronic insomnia: Implications for cardiovascular risk. Sleep. 2009;32(6):760–6. doi:10.1093/sleep/32.6.760</mixed-citation><mixed-citation xml:lang="en">Lanfranchi PA, Pennestri MH, Fradette L, Dumont M, Morin CM, Montplaisir J. Nighttime blood pressure in normotensive subjects with chronic insomnia: Implications for cardiovascular risk. Sleep. 2009;32(6):760–6. doi:10.1093/sleep/32.6.760</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126–33. doi:10.1161/HYPERTENSIONAHA.115.05449.REFRACTORY</mixed-citation><mixed-citation xml:lang="en">Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126–33. doi:10.1161/HYPERTENSIONAHA.115.05449.REFRACTORY</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. Circadian rhythms and cardiovascular health. Sleep Med Rev. 2012;16(2):151–66. doi:10.1016/jsmrv.2011.04.003</mixed-citation><mixed-citation xml:lang="en">Portaluppi F, Tiseo R, Smolensky MH, Hermida RC, Ayala DE, Fabbian F. Circadian rhythms and cardiovascular health. Sleep Med Rev. 2012;16(2):151–66. doi:10.1016/jsmrv.2011.04.003</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Crnko S, Du Pré BC, Sluijter JPG, Van Laake LW. Circadian rhythms and the molecular clock in cardiovascular biology and disease. Nat Rev Cardiol. 2019; doi:10.1038/s41569-019-0167-4</mixed-citation><mixed-citation xml:lang="en">Crnko S, Du Pré BC, Sluijter JPG, Van Laake LW. Circadian rhythms and the molecular clock in cardiovascular biology and disease. Nat Rev Cardiol. 2019; doi:10.1038/s41569-019-0167-4</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Одинак М. М., Денищук И. С. Особенности суточного профиля артериального давления у больных с прогредиентным течением гипертонической дисциркуляторной энцефалопатии. Вестник Российской Военно-медицинской академии. 2006; 2(16):26–9.</mixed-citation><mixed-citation xml:lang="en">Odinak MM, Denishchuk IS. Ciradican blood pressure profile in patients with progredient hypertensive discirculatory encephalopathy. Vestnik Rossiiskoi Voenno-medicinskoi akademii = Bulletin of the Russian Medical Military Academy.2006;2(16):26–9. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Одинак М. М., Хубулава Г. Г., Кузнецов А. Н., Вознюк И. А., Арсенова Н. А. Коррекция нарушения церебральной гемодинамики при артериальной гипертензии с помощью современных ингибиторов ангиотензин-превращающего фермента. Артериальная гипертензия. 2006;12(4):347–50.</mixed-citation><mixed-citation xml:lang="en">Odinak MM, Khubulava GG, Kuznetsov AN, Voznyuk IA, Arsenova NA. Correction of abnormal cerebral hemodynamics by novel angiotensin-converting enzyme inhibitors in hypertension. Arterial’naya Gipertenziya = Arterial Hypertension. 2006;12(4): 347–50. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Тихомирова О. В., Машкова Н. П., Маматова Н. Т., Котлярова Е. В., Сорокоумов В. А. Допплерографическая диагностика функционального состояния мозгового кровообращения при лакунарных инфарктах и артериальной гипертензии. Артериальная гипертензия. 2003;9(5):174–7.</mixed-citation><mixed-citation xml:lang="en">Tikhomirova OV, Mashkova NP, Mamatova Nt, Kotlyarova EV, Sorokoumov VA. Doppler diagnostics of cerebral circulation in lacunar stroke and hypertension. Arterial’naya Gipertenziya = Arterial Hypertension. 2003;9(5):174–7. In Russian.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Ga̧secki D, Kwarciany M, Nyka W, Narkiewicz K. Hypertension, brain damage and cognitive decline. Curr Hypertens Rep. 2013;15(6):547–58. doi:10.1007/s11906-013-0398-4</mixed-citation><mixed-citation xml:lang="en">Ga̧secki D, Kwarciany M, Nyka W, Narkiewicz K. Hypertension, brain damage and cognitive decline. Curr Hypertens Rep. 2013;15(6):547–58. doi:10.1007/s11906-013-0398-4</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Amenta F, Di Tullio MA, Tomassoni D. Arterial hypertension and brain damage — evidence from animal models. Clin Exp Hypertens. 2003;25(6):359–80. doi:10.1081/CEH‑120023545</mixed-citation><mixed-citation xml:lang="en">Amenta F, Di Tullio MA, Tomassoni D. Arterial hypertension and brain damage — evidence from animal models. Clin Exp Hypertens. 2003;25(6):359–80. doi:10.1081/CEH‑120023545</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Sierra C, Doménech M, Camafort M, Coca A. Hypertension and mild cognitive impairment. Current Hypertension Reports. 2012;14(6):548–55. doi:10.1007/s11906-012-0315-2</mixed-citation><mixed-citation xml:lang="en">Sierra C, Doménech M, Camafort M, Coca A. Hypertension and mild cognitive impairment. Current Hypertension Reports. 2012;14(6):548–55. doi:10.1007/s11906-012-0315-2</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Porter VR, Buxton WG, Avidan AY. Sleep, Cognition and dementia. Current Psychiatry Reports. 2015;17(97):1–11. doi:10.1007/s11920-015-0631-8</mixed-citation><mixed-citation xml:lang="en">Porter VR, Buxton WG, Avidan AY. Sleep, Cognition and dementia. Current Psychiatry Reports. 2015;17(97):1–11. doi:10.1007/s11920-015-0631-8</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Reid KJ, Baron KG, Lu B, Naylor E. Changes in cognitive performance are associated with changes in sleep in older adults with insomnia. Behav Sleep Med. 2016;14(3):295–310. doi:10.1016/j.sleep.2010.04.014.Aerobic</mixed-citation><mixed-citation xml:lang="en">Reid KJ, Baron KG, Lu B, Naylor E. Changes in cognitive performance are associated with changes in sleep in older adults with insomnia. Behav Sleep Med. 2016;14(3):295–310. doi:10.1016/j.sleep.2010.04.014.Aerobic</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang P, Tan C‑W, Chen G‑H, Ge Y‑J, Xu J, Xia L, et al. Patients with chronic insomnia disorder have increased serum levels of neurofilaments, neuron-specific enolase and S100B: does organic brain damage exist? Sleep Medicine. 2018;48:163–71. doi:https://doi.org/10.1016/j.sleep.2017.12.012</mixed-citation><mixed-citation xml:lang="en">Zhang P, Tan C‑W, Chen G‑H, Ge Y‑J, Xu J, Xia L, et al. Patients with chronic insomnia disorder have increased serum levels of neurofilaments, neuron-specific enolase and S100B: does organic brain damage exist? Sleep Medicine. 2018;48:163–71. doi:https://doi.org/10.1016/j.sleep.2017.12.012</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Joo EY, Noh HJ, Kim J‑S, Koo DL, Kim D, Hwang KJ, et al. Brain gray matter deficits in patients with chronic primary insomnia. Sleep. 2013;36(7):999–1007. doi:10.5665/sleep.2796</mixed-citation><mixed-citation xml:lang="en">Joo EY, Noh HJ, Kim J‑S, Koo DL, Kim D, Hwang KJ, et al. Brain gray matter deficits in patients with chronic primary insomnia. Sleep. 2013;36(7):999–1007. doi:10.5665/sleep.2796</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">O’Byrne JN, Berman Rosa M, Gouin JP, Dang-Vu TT. Neuroimaging findings in primary insomnia. Pathologie Biologie. 2014;62(5):262–9. doi:10.1016/j.patbio.2014.05.013</mixed-citation><mixed-citation xml:lang="en">O’Byrne JN, Berman Rosa M, Gouin JP, Dang-Vu TT. Neuroimaging findings in primary insomnia. Pathologie Biologie. 2014;62(5):262–9. doi:10.1016/j.patbio.2014.05.013</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Spiegelhalder K, Regen W, Prem M, Baglioni C, Nissen C, Feige B, et al. Reduced anterior internal capsule white matter integrity in primary insomnia. Human Brain Mapping. 2014;35(7): 3431–8. doi:10.1002/hbm.22412</mixed-citation><mixed-citation xml:lang="en">Spiegelhalder K, Regen W, Prem M, Baglioni C, Nissen C, Feige B, et al. Reduced anterior internal capsule white matter integrity in primary insomnia. Human Brain Mapping. 2014;35(7): 3431–8. doi:10.1002/hbm.22412</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Drake CL, Pillai V, Roth T. Stress and sleep reactivity: a prospective investigation of the stress-diathesis model of insomnia. Sleep. 2014;37(8):1295–304. doi:10.5665/sleep.3916</mixed-citation><mixed-citation xml:lang="en">Drake CL, Pillai V, Roth T. Stress and sleep reactivity: a prospective investigation of the stress-diathesis model of insomnia. Sleep. 2014;37(8):1295–304. doi:10.5665/sleep.3916</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. The Psychiatric clinics of North America. 1987;10(4):541–53.</mixed-citation><mixed-citation xml:lang="en">Spielman AJ, Caruso LS, Glovinsky PB. A behavioral perspective on insomnia treatment. The Psychiatric clinics of North America. 1987;10(4):541–53.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Xanthos DN, Sandkühler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nature Rev Neurosci. 2014;15(1):43–53. doi:10.1038/nrn3617</mixed-citation><mixed-citation xml:lang="en">Xanthos DN, Sandkühler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nature Rev Neurosci. 2014;15(1):43–53. doi:10.1038/nrn3617</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Rohleder N, Aringer M, Boentert M. Role of interleukin‑6 in stress, sleep, and fatigue. Annals of the New York Academy of Sciences. 2012;1261(1):88–96. doi:10.1111/j.1749-6632.2012.06634.x</mixed-citation><mixed-citation xml:lang="en">Rohleder N, Aringer M, Boentert M. Role of interleukin‑6 in stress, sleep, and fatigue. Annals of the New York Academy of Sciences. 2012;1261(1):88–96. doi:10.1111/j.1749-6632.2012.06634.x</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Hurtado-Alvarado G, Dominguez-Salazar E, Pavon L, Velazquez-Moctezuma J, Gomez-Gonzalez B. Blood-brain barrier disruption induced by chronic sleep loss: low-grade inflammation may be the link. J Immunol Res. 2016;2016 (4576012):1–15. doi:10.1155/2016/4576012</mixed-citation><mixed-citation xml:lang="en">Hurtado-Alvarado G, Dominguez-Salazar E, Pavon L, Velazquez-Moctezuma J, Gomez-Gonzalez B. Blood-brain barrier disruption induced by chronic sleep loss: low-grade inflammation may be the link. J Immunol Res. 2016;2016 (4576012):1–15. doi:10.1155/2016/4576012</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Heinzelmann M, Lee H, Rak H, Livingston W, Barr T, Baxter T, et al. Sleep restoration is associated with reduced plasma C‑reactive protein and depression symptoms in military personnel with sleep disturbance after deployment. Sleep Med. 2014;15 (12):1565–70. doi:10.1016/j.sleep.2014.08.004</mixed-citation><mixed-citation xml:lang="en">Heinzelmann M, Lee H, Rak H, Livingston W, Barr T, Baxter T, et al. Sleep restoration is associated with reduced plasma C‑reactive protein and depression symptoms in military personnel with sleep disturbance after deployment. Sleep Med. 2014;15 (12):1565–70. doi:10.1016/j.sleep.2014.08.004</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Erta M, Quintana A, Hidalgo J. Interleukin‑6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9): 1254–66. doi:10.7150/ijbs.4679</mixed-citation><mixed-citation xml:lang="en">Erta M, Quintana A, Hidalgo J. Interleukin‑6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9): 1254–66. doi:10.7150/ijbs.4679</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Benedict C, Scheller J, Rose-John S, Born J, Marshall L. Enhancing influence of intranasal interleukin‑6 on slow-wave activity and memory consolidation during sleep. The FASEB J. 2009;23(10):3629–36. doi:10.1096/fj.08–122853</mixed-citation><mixed-citation xml:lang="en">Benedict C, Scheller J, Rose-John S, Born J, Marshall L. Enhancing influence of intranasal interleukin‑6 on slow-wave activity and memory consolidation during sleep. The FASEB J. 2009;23(10):3629–36. doi:10.1096/fj.08–122853</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Burgos I, Richter L, Klein T, Fiebich B, Feige B, Lieb K, et al. Increased nocturnal interleukin‑6 excretion in patients with primary insomnia: a pilot study. Brain, Behavior, and Immunity. 2006;20(3):246–53. doi:10.1016/j.bbi.2005.06.007</mixed-citation><mixed-citation xml:lang="en">Burgos I, Richter L, Klein T, Fiebich B, Feige B, Lieb K, et al. Increased nocturnal interleukin‑6 excretion in patients with primary insomnia: a pilot study. Brain, Behavior, and Immunity. 2006;20(3):246–53. doi:10.1016/j.bbi.2005.06.007</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Vgontzas AN, Zoumakis M, Papanicolaou DA, Bixler EO, Prolo P, Lin HM, et al. Chronic insomnia is associated with a shift of interleukin‑6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism. 2002;51(7):887–92. doi:10.1053/meta.2002.33357</mixed-citation><mixed-citation xml:lang="en">Vgontzas AN, Zoumakis M, Papanicolaou DA, Bixler EO, Prolo P, Lin HM, et al. Chronic insomnia is associated with a shift of interleukin‑6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism. 2002;51(7):887–92. doi:10.1053/meta.2002.33357</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Irwin MR, Olmstead R, Breen EC, Witarama T, Carrillo C, Sadeghi N, et al. Tai Chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: A randomized controlled trial. J Nat Cancer Institute. 2014;2014 (50):295–301. doi:10.1093/jncimonographs/lgu028</mixed-citation><mixed-citation xml:lang="en">Irwin MR, Olmstead R, Breen EC, Witarama T, Carrillo C, Sadeghi N, et al. Tai Chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: A randomized controlled trial. J Nat Cancer Institute. 2014;2014 (50):295–301. doi:10.1093/jncimonographs/lgu028</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Irwin MR, Olmstead R, Breen EC, Witarama T, Carrillo C, Sadeghi N, et al. Cognitive behavioral therapy and tai chi reverse cellular and genomic markers of inflammation in late-life insomnia: a randomized controlled trial. Biological Psychiatry. 2015;78(10): 721–9. doi:10.1016/j.biopsych.2015.01.010</mixed-citation><mixed-citation xml:lang="en">Irwin MR, Olmstead R, Breen EC, Witarama T, Carrillo C, Sadeghi N, et al. Tai Chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: A randomized controlled trial. J Nat Cancer Institute. 2014;2014 (50):295–301. doi:10.1093/jncimonographs/lgu028</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. BioMed Research International. 2014;2014 (406960): 1–11. doi:10.1155/2014/406960</mixed-citation><mixed-citation xml:lang="en">Irwin MR, Olmstead R, Breen EC, Witarama T, Carrillo C, Sadeghi N, et al. Cognitive behavioral therapy and tai chi reverse cellular and genomic markers of inflammation in late-life insomnia: a randomized controlled trial. Biological Psychiatry. 2015;78(10): 721–9. doi:10.1016/j.biopsych.2015.01.010</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Chamarthi B, Williams GH, Ricchiuti V, Srikumar N, Hopkins PN, Luther JM, et al. Inflammation hypertension: the interplay of interleukin‑6, dietary sodium and the reninangiotensin system in humans. Am J Hypertens. 2011;24(10):1–13. doi:10.1038/ajh.2011.113.Inflammation</mixed-citation><mixed-citation xml:lang="en">Irwin MR, Olmstead R, Breen EC, Witarama T, Carrillo C, Sadeghi N, et al. Cognitive behavioral therapy and tai chi reverse cellular and genomic markers of inflammation in late-life insomnia: a randomized controlled trial. Biological Psychiatry. 2015;78(10): 721–9. doi:10.1016/j.biopsych.2015.01.010</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Hashmat S, Rudemiller N, Lund H, Abais-Battad JM, Van Why S, Mattson DL. Interleukin‑6 inhibition attenuates hypertension and associated renal damage in Dahl salt-sensitive rats. Am J Renal Physiol. 2016;311 (3):555–61. doi:10.1152/ajprenal.00594.2015</mixed-citation><mixed-citation xml:lang="en">Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. BioMed Research International. 2014;2014 (406960): 1–11. doi:10.1155/2014/406960</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Heijnen BFJ, Van Essen H, Schalkwijk CG, Janssen BJA, Struijker-Boudier HAJ. Renal inflammatory markers during the onset of hypertension in spontaneously hypertensive rats. Рнзукеу-ты Куы. 2014;37(2):100–9. doi:10.1038/hr.2013.99</mixed-citation><mixed-citation xml:lang="en">Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. BioMed Research International. 2014;2014 (406960): 1–11. doi:10.1155/2014/406960</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Rodriguez-Iturbe B, Johnson RJ. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrology Dialysis Transplantation. 2006;21(2):260–3. doi:10.1093/ndt/gfi319</mixed-citation><mixed-citation xml:lang="en">Chamarthi B, Williams GH, Ricchiuti V, Srikumar N, Hopkins PN, Luther JM, et al. Inflammation hypertension: the interplay of interleukin‑6, dietary sodium and the reninangiotensin system in humans. Am J Hypertens. 2011;24(10):1–13. doi:10.1038/ajh.2011.113.Inflammation</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Mao SQ, Sun JH, Gu TL, Zhu FB, Yin FY, Zhang LN. Hypomethylation of interleukin‑6 (IL‑6) gene increases the risk of essential hypertension: a matched case-control study. J Hum Hypertens. 2017;31(8):530–6. doi:10.1038/jhh.2017.7</mixed-citation><mixed-citation xml:lang="en">Chamarthi B, Williams GH, Ricchiuti V, Srikumar N, Hopkins PN, Luther JM, et al. Inflammation hypertension: the interplay of interleukin‑6, dietary sodium and the reninangiotensin system in humans. Am J Hypertens. 2011;24(10):1–13. doi:10.1038/ajh.2011.113.Inflammation</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Tamura Y, Phan C, Tu L, Le Hiress M, Thuillet R, Jutant EM, et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. JJ Clin Invest. 2018;128(5):1956–70. doi:10.1172/JCI96462</mixed-citation><mixed-citation xml:lang="en">Hashmat S, Rudemiller N, Lund H, Abais-Battad JM, Van Why S, Mattson DL. Interleukin‑6 inhibition attenuates hypertension and associated renal damage in Dahl salt-sensitive rats. Am J Renal Physiol. 2016;311 (3):555–61. doi:10.1152/ajprenal.00594.2015</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Schölzel BE, Post MC, Dymarkowski S, Wuyts W, Meyns B, Budts W, et al. Plasma interleukin‑6 adds prognostic information in pulmonary arterial hypertension. Eur Resp J. 2014;43(3):909–12. doi:10.1183/09031936.00174113</mixed-citation><mixed-citation xml:lang="en">Hashmat S, Rudemiller N, Lund H, Abais-Battad JM, Van Why S, Mattson DL. Interleukin‑6 inhibition attenuates hypertension and associated renal damage in Dahl salt-sensitive rats. Am J Renal Physiol. 2016;311 (3):555–61. doi:10.1152/ajprenal.00594.2015</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Pullamsetti SS, Seeger W, Savai R. Classical IL‑6 signaling: a promising therapeutic target for pulmonary arterial hypertension. J Clin Invest. 2018;128(5):1720–3. doi:10.1172/JCI120415</mixed-citation><mixed-citation xml:lang="en">Heijnen BFJ, Van Essen H, Schalkwijk CG, Janssen BJA, Struijker-Boudier HAJ. Renal inflammatory markers during the onset of hypertension in spontaneously hypertensive rats. Рнзукеу-ты Куы. 2014;37(2):100–9. doi:10.1038/hr.2013.99</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Gottesmann C. GABA mechanisms and sleep. Neuroscience. 2002;111(2):231–9. doi:10.1016/S0306-4522(02)00034-9</mixed-citation><mixed-citation xml:lang="en">Heijnen BFJ, Van Essen H, Schalkwijk CG, Janssen BJA, Struijker-Boudier HAJ. Renal inflammatory markers during the onset of hypertension in spontaneously hypertensive rats. Рнзукеу-ты Куы. 2014;37(2):100–9. doi:10.1038/hr.2013.99</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Plante DT, Jensen JE, Schoerning L, Winkelman JW. Reduced γ-aminobutyric acid in occipital and anterior cingulate cortices in primary insomnia: a link to major depressive disorder. Neuropsychopharmacology. 2012;37(6):1548–57. doi:10.1038/npp.2012.4</mixed-citation><mixed-citation xml:lang="en">Rodriguez-Iturbe B, Johnson RJ. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrology Dialysis Transplantation. 2006;21(2):260–3. doi:10.1093/ndt/gfi319</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Winkelman, Buxton, Jensen, Benson, O’Connor, Wang C et al. Reduced brain GABA in primary insomnia: preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS). Sleep. 2008;31(11):1499–506.</mixed-citation><mixed-citation xml:lang="en">Rodriguez-Iturbe B, Johnson RJ. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrology Dialysis Transplantation. 2006;21(2):260–3. doi:10.1093/ndt/gfi319</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Chen HH, Cheng PW, Ho WY, Lu PJ, Lai CC, Tseng YM, et al. Renal denervation improves the baroreflex and GABA system in chronic kidney disease-induced hypertension. Scientific Reports. 2016;6(38447):1–13. doi:10.1038/srep38447</mixed-citation><mixed-citation xml:lang="en">Mao SQ, Sun JH, Gu TL, Zhu FB, Yin FY, Zhang LN. Hypomethylation of interleukin‑6 (IL‑6) gene increases the risk of essential hypertension: a matched case-control study. J Hum Hypertens. 2017;31(8):530–6. doi:10.1038/jhh.2017.7</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Ma P, Li T, Ji F, Wang H, Pang J. Effect of GABA on blood pressure and blood dynamics of anesthetic rats. Int J Clin Exp Med. 2015;8(8):14296–302.</mixed-citation><mixed-citation xml:lang="en">Mao SQ, Sun JH, Gu TL, Zhu FB, Yin FY, Zhang LN. Hypomethylation of interleukin‑6 (IL‑6) gene increases the risk of essential hypertension: a matched case-control study. J Hum Hypertens. 2017;31(8):530–6. doi:10.1038/jhh.2017.7</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Mei L, Zhang J, Mifflin S. Hypertension alters GABA receptor-mediated inhibition of neurons in the nucleus of the solitary tract. Am J Physiology-Regulatory, Integrative and Comparative Physiology. 2003;285(6):1276–86. doi:10.1152/ajpregu.00255.2003</mixed-citation><mixed-citation xml:lang="en">Tamura Y, Phan C, Tu L, Le Hiress M, Thuillet R, Jutant EM, et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. JJ Clin Invest. 2018;128(5):1956–70. doi:10.1172/JCI96462</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Shimada M, Hasegawa T, Nishimura C, Kan H, Kanno T, Nakamura T, et al. Anti-hypertensive effect of gamma-aminobutyric acid (GABA) rich Chlorella on high normal blood pressure and borderline hypertension in placebo-controlled double blind study. J Clin Exp Hypertens. 2019;31(4):342–54.</mixed-citation><mixed-citation xml:lang="en">Tamura Y, Phan C, Tu L, Le Hiress M, Thuillet R, Jutant EM, et al. Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. JJ Clin Invest. 2018;128(5):1956–70. doi:10.1172/JCI96462</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Byun JI, Shin YY, Chung SE, Shin WC. Safety and efficacy of gamma-aminobutyric acid from fermented rice germ in patients with insomnia symptoms: A randomized, double-blind trial. J Clin Neurol (Korea). 2018;14(3):291–5. doi:10.3988/jcn.2018.14.3.291</mixed-citation><mixed-citation xml:lang="en">Schölzel BE, Post MC, Dymarkowski S, Wuyts W, Meyns B, Budts W, et al. Plasma interleukin‑6 adds prognostic information in pulmonary arterial hypertension. Eur Resp J. 2014;43(3):909–12. doi:10.1183/09031936.00174113</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Ursavas A. Upregulating substance P levels to treat obstructive sleep apnea. Expert Opinion on Therapeutic Targets. 2008;12(5):583–8. doi:10.1517/14728222.12.5.583</mixed-citation><mixed-citation xml:lang="en">Schölzel BE, Post MC, Dymarkowski S, Wuyts W, Meyns B, Budts W, et al. Plasma interleukin‑6 adds prognostic information in pulmonary arterial hypertension. Eur Resp J. 2014;43(3):909–12. doi:10.1183/09031936.00174113</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y, Wang DH. Role of substance P in renal injury during DOCA-salt hypertension. Endocrinology. 2012;153 (12):5972–9. doi:10.1210/en.2012-1284</mixed-citation><mixed-citation xml:lang="en">Pullamsetti SS, Seeger W, Savai R. Classical IL‑6 signaling: a promising therapeutic target for pulmonary arterial hypertension. J Clin Invest. 2018;128(5):1720–3. doi:10.1172/JCI120415</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Ratti E, Carpenter DJ, Zamuner S, Fernandes S, Squassante L, Danker-Hopfe H, et al. Efficacy of vestipitant, a neurokinin‑1 receptor antagonist, in primary insomnia. Sleep. 2013;36(12):1823–30. doi:10.5665/sleep.3208</mixed-citation><mixed-citation xml:lang="en">Pullamsetti SS, Seeger W, Savai R. Classical IL‑6 signaling: a promising therapeutic target for pulmonary arterial hypertension. J Clin Invest. 2018;128(5):1720–3. doi:10.1172/JCI120415</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis &amp; Rheumatism. 1994;37(11):1593–601. doi:10.1002/art.1780371106</mixed-citation><mixed-citation xml:lang="en">Gottesmann C. GABA mechanisms and sleep. Neuroscience. 2002;111(2):231–9. doi:10.1016/S0306-4522(02)00034-9</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology. 2002;27(6):1041–9. doi:10.1016/S0893-133X(02)00369‑X</mixed-citation><mixed-citation xml:lang="en">Gottesmann C. GABA mechanisms and sleep. Neuroscience. 2002;111(2):231–9. doi:10.1016/S0306-4522(02)00034-9</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz TL, Goradia V. Managing insomnia: An overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs in Context. 2013;1–10. doi:10.7573/dic.212257</mixed-citation><mixed-citation xml:lang="en">Plante DT, Jensen JE, Schoerning L, Winkelman JW. Reduced γ-aminobutyric acid in occipital and anterior cingulate cortices in primary insomnia: a link to major depressive disorder. Neuropsychopharmacology. 2012;37(6):1548–57. doi:10.1038/npp.2012.4</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Kohlmann O, Cesaretti ML, Ginoza M, Tavares A, Zanella MT, Ribeiro AB, et al. Role of substance P in blood pressure regulation in salt-dependent experimental hypertension. Hypertension. 1997;29(1):506–9. doi:10.1161/01.hyp.29.1.506</mixed-citation><mixed-citation xml:lang="en">Plante DT, Jensen JE, Schoerning L, Winkelman JW. Reduced γ-aminobutyric acid in occipital and anterior cingulate cortices in primary insomnia: a link to major depressive disorder. Neuropsychopharmacology. 2012;37(6):1548–57. doi:10.1038/npp.2012.4</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Faulhaber HD, Oehme P, Baumann R, Enderlein J, Rathsack R, Rostock G, et al. Substance P in human essential hypertension. J Cardiovasc Pharmacol. 2008;10 (Sup 12):172–6. doi:10.1097/00005344-198710012-00029</mixed-citation><mixed-citation xml:lang="en">Winkelman, Buxton, Jensen, Benson, O’Connor, Wang C et al. Reduced brain GABA in primary insomnia: preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS). Sleep. 2008;31(11):1499–506.</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Mori K, Asakura S, Ogawa H, Sasagawa S, Takeyama M. Decreases in Substance P and vasoactive intestinal peptide concentrations in plasma of stroke-prone spontaneously hypertensive rats. Jap Heart J. 1993;34(6):785–94. doi:10.1536/ihj.34.785</mixed-citation><mixed-citation xml:lang="en">Winkelman, Buxton, Jensen, Benson, O’Connor, Wang C et al. Reduced brain GABA in primary insomnia: preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS). Sleep. 2008;31(11):1499–506.</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Dehlin HM, Manteufel EJ, Monroe AL, Reimer MHJ, Levick SP. Substance P acting via the neurokinin‑1 receptor regulates adverse myocardial remodeling in a rat model of hypertension. Int J Cardiol. 2013;168(5):4643–4651. doi:10.1007/s00246-012-0450-1.A</mixed-citation><mixed-citation xml:lang="en">Chen HH, Cheng PW, Ho WY, Lu PJ, Lai CC, Tseng YM, et al. Renal denervation improves the baroreflex and GABA system in chronic kidney disease-induced hypertension. Scientific Reports. 2016;6(38447):1–13. doi:10.1038/srep38447</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Meléndez GC, Li J, Law BA, Janicki JS, Supowit SC, Levick SP. Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells. Cardiovasc Res. 2011;92(3):420–9. doi:10.1093/cvr/cvr244</mixed-citation><mixed-citation xml:lang="en">Chen HH, Cheng PW, Ho WY, Lu PJ, Lai CC, Tseng YM, et al. Renal denervation improves the baroreflex and GABA system in chronic kidney disease-induced hypertension. Scientific Reports. 2016;6(38447):1–13. doi:10.1038/srep38447</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Chen L‑W, Chen C‑F, Lai Y‑L. Chronic activation of neurokinin‑1 receptor induces pulmonary hypertension in rats. Am J Physiol. 1999;276(5):1543–51. doi:10.1152/ajpheart.1999.276.5.h1543</mixed-citation><mixed-citation xml:lang="en">Ma P, Li T, Ji F, Wang H, Pang J. Effect of GABA on blood pressure and blood dynamics of anesthetic rats. Int J Clin Exp Med. 2015;8(8):14296–302.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Katsi V, Karagiorgi I, Makris T, Papavasileiou M, Androulakis AE, Tsioufis C, et al. The role of melatonin in hypertension. Cardiovasc Endocrinol. 2012;1(1):13–8. doi:10.1097/xce.0b013e3283565783</mixed-citation><mixed-citation xml:lang="en">Ma P, Li T, Ji F, Wang H, Pang J. Effect of GABA on blood pressure and blood dynamics of anesthetic rats. Int J Clin Exp Med. 2015;8(8):14296–302.</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Grossman E. Should melatonin be used to lower blood pressure? Hypertens Res. 2013;36(8):682–3. doi:10.1038/hr.2013.29</mixed-citation><mixed-citation xml:lang="en">Mei L, Zhang J, Mifflin S. Hypertension alters GABA receptor-mediated inhibition of neurons in the nucleus of the solitary tract. Am J Physiology-Regulatory, Integrative and Comparative Physiology. 2003;285(6):1276–86. doi:10.1152/ajpregu.00255.2003</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vascular Health and Risk Management. 2011;7(1):577–84. doi:10.2147/VHRM.S24603</mixed-citation><mixed-citation xml:lang="en">Mei L, Zhang J, Mifflin S. Hypertension alters GABA receptor-mediated inhibition of neurons in the nucleus of the solitary tract. Am J Physiology-Regulatory, Integrative and Comparative Physiology. 2003;285(6):1276–86. doi:10.1152/ajpregu.00255.2003</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116–22. doi:10.1111/j.1600-079X.1995.tb00179.x</mixed-citation><mixed-citation xml:lang="en">Shimada M, Hasegawa T, Nishimura C, Kan H, Kanno T, Nakamura T, et al. Anti-hypertensive effect of gamma-aminobutyric acid (GABA) rich Chlorella on high normal blood pressure and borderline hypertension in placebo-controlled double blind study. J Clin Exp Hypertens. 2019;31(4):342–54.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Niederhofer H, Staffen W, Mair A, Pittschieler K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Developmental Disorders. 2003;33(4):469–72. doi:10.1023/A:1025027231938</mixed-citation><mixed-citation xml:lang="en">Shimada M, Hasegawa T, Nishimura C, Kan H, Kanno T, Nakamura T, et al. Anti-hypertensive effect of gamma-aminobutyric acid (GABA) rich Chlorella on high normal blood pressure and borderline hypertension in placebo-controlled double blind study. J Clin Exp Hypertens. 2019;31(4):342–54.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: A randomised controlled trial. BMC Medicine. 2018;16(1):1–10. doi:10.1186/s12916-017-0995-1</mixed-citation><mixed-citation xml:lang="en">Byun JI, Shin YY, Chung SE, Shin WC. Safety and efficacy of gamma-aminobutyric acid from fermented rice germ in patients with insomnia symptoms: A randomized, double-blind trial. J Clin Neurol (Korea). 2018;14(3):291–5. doi:10.3988/jcn.2018.14.3.291</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion. 2007;23 (10):2597–605. doi:10.1185/030079907X233098</mixed-citation><mixed-citation xml:lang="en">Byun JI, Shin YY, Chung SE, Shin WC. Safety and efficacy of gamma-aminobutyric acid from fermented rice germ in patients with insomnia symptoms: A randomized, double-blind trial. J Clin Neurol (Korea). 2018;14(3):291–5. doi:10.3988/jcn.2018.14.3.291</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Van Maanen A, Meijer AM, Smits MG, Van Der Heijden KB, Oort FJ. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017; 40(2):1–11. doi:10.1093/sleep/zsw038</mixed-citation><mixed-citation xml:lang="en">Ursavas A. Upregulating substance P levels to treat obstructive sleep apnea. Expert Opinion on Therapeutic Targets. 2008;12(5):583–8. doi:10.1517/14728222.12.5.583</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):307–49. doi:10.5664/jcsm.6506</mixed-citation><mixed-citation xml:lang="en">Ursavas A. Upregulating substance P levels to treat obstructive sleep apnea. Expert Opinion on Therapeutic Targets. 2008;12(5):583–8. doi:10.1517/14728222.12.5.583</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Fraer M, Kilic F. Serotonin: a different player in hypertensionassociated thrombosis. Hypertension. 2015;65(5):942–8. doi:10.1161/HYPERTENSIONAHA.114.05061</mixed-citation><mixed-citation xml:lang="en">Wang Y, Wang DH. Role of substance P in renal injury during DOCA-salt hypertension. Endocrinology. 2012;153 (12):5972–9. doi:10.1210/en.2012-1284</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru">Cespuglio R. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. 2018;(49):31–9. doi:10.1016/j.sleep.2018.05.034</mixed-citation><mixed-citation xml:lang="en">Wang Y, Wang DH. Role of substance P in renal injury during DOCA-salt hypertension. Endocrinology. 2012;153 (12):5972–9. doi:10.1210/en.2012-1284</mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru">Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15(4):269–81. doi:10.1016/j.smrv.2010.11.003</mixed-citation><mixed-citation xml:lang="en">Ratti E, Carpenter DJ, Zamuner S, Fernandes S, Squassante L, Danker-Hopfe H, et al. Efficacy of vestipitant, a neurokinin‑1 receptor antagonist, in primary insomnia. Sleep. 2013;36(12):1823–30. doi:10.5665/sleep.3208</mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru">Murray NM, Buchanan GF, Richerson GB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep. 2015;38 (12):1985–93. doi:10.5665/sleep.5256</mixed-citation><mixed-citation xml:lang="en">Ratti E, Carpenter DJ, Zamuner S, Fernandes S, Squassante L, Danker-Hopfe H, et al. Efficacy of vestipitant, a neurokinin‑1 receptor antagonist, in primary insomnia. Sleep. 2013;36(12):1823–30. doi:10.5665/sleep.3208</mixed-citation></citation-alternatives></ref><ref id="cit101"><label>101</label><citation-alternatives><mixed-citation xml:lang="ru">Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 2013:62:324–39. doi:10.1016/j.neuint.2012.12.014</mixed-citation><mixed-citation xml:lang="en">Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis &amp; Rheumatism. 1994;37(11):1593–601. doi:10.1002/art.1780371106</mixed-citation></citation-alternatives></ref><ref id="cit102"><label>102</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin‑1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):1–9. doi:10.1186/s12888-016-1025-0</mixed-citation><mixed-citation xml:lang="en">Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis &amp; Rheumatism. 1994;37(11):1593–601. doi:10.1002/art.1780371106</mixed-citation></citation-alternatives></ref><ref id="cit103"><label>103</label><citation-alternatives><mixed-citation xml:lang="ru">Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler HB, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):1–15. doi:10.1371/journal.pone.0143397</mixed-citation><mixed-citation xml:lang="en">Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology. 2002;27(6):1041–9. doi:10.1016/S0893-133X(02)00369‑X</mixed-citation></citation-alternatives></ref><ref id="cit104"><label>104</label><citation-alternatives><mixed-citation xml:lang="ru">Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–88. doi:10.1124/pr.111.004697</mixed-citation><mixed-citation xml:lang="en">Lieb K, Ahlvers K, Dancker K, Strohbusch S, Reincke M, Feige B, et al. Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology. 2002;27(6):1041–9. doi:10.1016/S0893-133X(02)00369‑X</mixed-citation></citation-alternatives></ref><ref id="cit105"><label>105</label><citation-alternatives><mixed-citation xml:lang="ru">Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation [Internet]. Biomed Pharmacother. 2017;90:187–93. doi:10.1016/j.biopha.2017.03.053</mixed-citation><mixed-citation xml:lang="en">Schwartz TL, Goradia V. Managing insomnia: An overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs in Context. 2013;1–10. doi:10.7573/dic.212257</mixed-citation></citation-alternatives></ref><ref id="cit106"><label>106</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Implicating the potential role of orexin in hypertension. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2017;390(7):667–76. doi:10.1007/s00210-017-1378‑z</mixed-citation><mixed-citation xml:lang="en">Schwartz TL, Goradia V. Managing insomnia: An overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs in Context. 2013;1–10. doi:10.7573/dic.212257</mixed-citation></citation-alternatives></ref><ref id="cit107"><label>107</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: evidences &amp; mechanisms. Neuropeptides. 2018;68:1–6. doi:10.1016/j.npep.2018.02.002</mixed-citation><mixed-citation xml:lang="en">Kohlmann O, Cesaretti ML, Ginoza M, Tavares A, Zanella MT, Ribeiro AB, et al. Role of substance P in blood pressure regulation in salt-dependent experimental hypertension. Hypertension. 1997;29(1):506–9. doi:10.1161/01.hyp.29.1.506</mixed-citation></citation-alternatives></ref><ref id="cit108"><label>108</label><citation-alternatives><mixed-citation xml:lang="ru">Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology. 2013; 4:1–10. doi:10.3389/fendo.2013.00018</mixed-citation><mixed-citation xml:lang="en">Kohlmann O, Cesaretti ML, Ginoza M, Tavares A, Zanella MT, Ribeiro AB, et al. Role of substance P in blood pressure regulation in salt-dependent experimental hypertension. Hypertension. 1997;29(1):506–9. doi:10.1161/01.hyp.29.1.506</mixed-citation></citation-alternatives></ref><ref id="cit109"><label>109</label><citation-alternatives><mixed-citation xml:lang="ru">Silvani A. Orexins and the cardiovascular events of awakening. Temperature. 2017;4(2):128–40. doi:10.1080/23328940.2017.1295128</mixed-citation><mixed-citation xml:lang="en">Faulhaber HD, Oehme P, Baumann R, Enderlein J, Rathsack R, Rostock G, et al. Substance P in human essential hypertension. J Cardiovasc Pharmacol. 2008;10 (Sup 12):172–6. doi:10.1097/00005344-198710012-00029</mixed-citation></citation-alternatives></ref><ref id="cit110"><label>110</label><citation-alternatives><mixed-citation xml:lang="ru">Prober DA, Rihel J, Onah AA, Sung R‑J, Schier AF. Hypocretin/Orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26 (51):13400–10. doi:10.1523/JNEUROSCI.4332–06.2006</mixed-citation><mixed-citation xml:lang="en">Faulhaber HD, Oehme P, Baumann R, Enderlein J, Rathsack R, Rostock G, et al. Substance P in human essential hypertension. J Cardiovasc Pharmacol. 2008;10 (Sup 12):172–6. doi:10.1097/00005344-198710012-00029</mixed-citation></citation-alternatives></ref><ref id="cit111"><label>111</label><citation-alternatives><mixed-citation xml:lang="ru">Tang S, Huang W, Lu S, Lu L, Li G, Chen X, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61. doi:10.1016/j.peptides.2016.12.008</mixed-citation><mixed-citation xml:lang="en">Mori K, Asakura S, Ogawa H, Sasagawa S, Takeyama M. Decreases in Substance P and vasoactive intestinal peptide concentrations in plasma of stroke-prone spontaneously hypertensive rats. Jap Heart J. 1993;34(6):785–94. doi:10.1536/ihj.34.785</mixed-citation></citation-alternatives></ref><ref id="cit112"><label>112</label><citation-alternatives><mixed-citation xml:lang="ru">Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kanna H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277(6):1780–5.</mixed-citation><mixed-citation xml:lang="en">Mori K, Asakura S, Ogawa H, Sasagawa S, Takeyama M. Decreases in Substance P and vasoactive intestinal peptide concentrations in plasma of stroke-prone spontaneously hypertensive rats. Jap Heart J. 1993;34(6):785–94. doi:10.1536/ihj.34.785</mixed-citation></citation-alternatives></ref><ref id="cit113"><label>113</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Hindmarch CCT, Nattie EE, Paton JFR. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591(17):4237–48 doi:10.1113/jphysiol.2013.256271</mixed-citation><mixed-citation xml:lang="en">Dehlin HM, Manteufel EJ, Monroe AL, Reimer MHJ, Levick SP. Substance P acting via the neurokinin‑1 receptor regulates adverse myocardial remodeling in a rat model of hypertension. Int J Cardiol. 2013;168(5):4643–4651. doi:10.1007/s00246-012-0450-1.A</mixed-citation></citation-alternatives></ref><ref id="cit114"><label>114</label><citation-alternatives><mixed-citation xml:lang="ru">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation><mixed-citation xml:lang="en">Dehlin HM, Manteufel EJ, Monroe AL, Reimer MHJ, Levick SP. Substance P acting via the neurokinin‑1 receptor regulates adverse myocardial remodeling in a rat model of hypertension. Int J Cardiol. 2013;168(5):4643–4651. doi:10.1007/s00246-012-0450-1.A</mixed-citation></citation-alternatives></ref><ref id="cit115"><label>115</label><citation-alternatives><mixed-citation xml:lang="ru">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation><mixed-citation xml:lang="en">Meléndez GC, Li J, Law BA, Janicki JS, Supowit SC, Levick SP. Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells. Cardiovasc Res. 2011;92(3):420–9. doi:10.1093/cvr/cvr244</mixed-citation></citation-alternatives></ref><ref id="cit116"><label>116</label><citation-alternatives><mixed-citation xml:lang="ru">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation><mixed-citation xml:lang="en">Meléndez GC, Li J, Law BA, Janicki JS, Supowit SC, Levick SP. Substance P induces adverse myocardial remodelling via a mechanism involving cardiac mast cells. Cardiovasc Res. 2011;92(3):420–9. doi:10.1093/cvr/cvr244</mixed-citation></citation-alternatives></ref><ref id="cit117"><label>117</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation><mixed-citation xml:lang="en">Chen L‑W, Chen C‑F, Lai Y‑L. Chronic activation of neurokinin‑1 receptor induces pulmonary hypertension in rats. Am J Physiol. 1999;276(5):1543–51. doi:10.1152/ajpheart.1999.276.5.h1543</mixed-citation></citation-alternatives></ref><ref id="cit118"><label>118</label><citation-alternatives><mixed-citation xml:lang="ru">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation><mixed-citation xml:lang="en">Chen L‑W, Chen C‑F, Lai Y‑L. Chronic activation of neurokinin‑1 receptor induces pulmonary hypertension in rats. Am J Physiol. 1999;276(5):1543–51. doi:10.1152/ajpheart.1999.276.5.h1543</mixed-citation></citation-alternatives></ref><ref id="cit119"><label>119</label><citation-alternatives><mixed-citation xml:lang="ru">Katsi V, Karagiorgi I, Makris T, Papavasileiou M, Androulakis AE, Tsioufis C, et al. The role of melatonin in hypertension. Cardiovasc Endocrinol. 2012;1(1):13–8. doi:10.1097/xce.0b013e3283565783</mixed-citation><mixed-citation xml:lang="en">Katsi V, Karagiorgi I, Makris T, Papavasileiou M, Androulakis AE, Tsioufis C, et al. The role of melatonin in hypertension. Cardiovasc Endocrinol. 2012;1(1):13–8. doi:10.1097/xce.0b013e3283565783</mixed-citation></citation-alternatives></ref><ref id="cit120"><label>120</label><citation-alternatives><mixed-citation xml:lang="ru">Katsi V, Karagiorgi I, Makris T, Papavasileiou M, Androulakis AE, Tsioufis C, et al. The role of melatonin in hypertension. Cardiovasc Endocrinol. 2012;1(1):13–8. doi:10.1097/xce.0b013e3283565783</mixed-citation><mixed-citation xml:lang="en">Katsi V, Karagiorgi I, Makris T, Papavasileiou M, Androulakis AE, Tsioufis C, et al. The role of melatonin in hypertension. Cardiovasc Endocrinol. 2012;1(1):13–8. doi:10.1097/xce.0b013e3283565783</mixed-citation></citation-alternatives></ref><ref id="cit121"><label>121</label><citation-alternatives><mixed-citation xml:lang="ru">Grossman E. Should melatonin be used to lower blood pressure? Hypertens Res. 2013;36(8):682–3. doi:10.1038/hr.2013.29</mixed-citation><mixed-citation xml:lang="en">Grossman E. Should melatonin be used to lower blood pressure? Hypertens Res. 2013;36(8):682–3. doi:10.1038/hr.2013.29</mixed-citation></citation-alternatives></ref><ref id="cit122"><label>122</label><citation-alternatives><mixed-citation xml:lang="ru">Grossman E. Should melatonin be used to lower blood pressure? Hypertens Res. 2013;36(8):682–3. doi:10.1038/hr.2013.29</mixed-citation><mixed-citation xml:lang="en">Grossman E. Should melatonin be used to lower blood pressure? Hypertens Res. 2013;36(8):682–3. doi:10.1038/hr.2013.29</mixed-citation></citation-alternatives></ref><ref id="cit123"><label>123</label><citation-alternatives><mixed-citation xml:lang="ru">Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vascular Health and Risk Management. 2011;7(1):577–84. doi:10.2147/VHRM.S24603</mixed-citation><mixed-citation xml:lang="en">Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vascular Health and Risk Management. 2011;7(1):577–84. doi:10.2147/VHRM.S24603</mixed-citation></citation-alternatives></ref><ref id="cit124"><label>124</label><citation-alternatives><mixed-citation xml:lang="ru">Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vascular Health and Risk Management. 2011;7(1):577–84. doi:10.2147/VHRM.S24603</mixed-citation><mixed-citation xml:lang="en">Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vascular Health and Risk Management. 2011;7(1):577–84. doi:10.2147/VHRM.S24603</mixed-citation></citation-alternatives></ref><ref id="cit125"><label>125</label><citation-alternatives><mixed-citation xml:lang="ru">Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vascular Health and Risk Management. 2011;7(1):577–84. doi:10.2147/VHRM.S24603</mixed-citation><mixed-citation xml:lang="en">Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vascular Health and Risk Management. 2011;7(1):577–84. doi:10.2147/VHRM.S24603</mixed-citation></citation-alternatives></ref><ref id="cit126"><label>126</label><citation-alternatives><mixed-citation xml:lang="ru">Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116–22. doi:10.1111/j.1600-079X.1995.tb00179.x</mixed-citation><mixed-citation xml:lang="en">Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116–22. doi:10.1111/j.1600-079X.1995.tb00179.x</mixed-citation></citation-alternatives></ref><ref id="cit127"><label>127</label><citation-alternatives><mixed-citation xml:lang="ru">Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116–22. doi:10.1111/j.1600-079X.1995.tb00179.x</mixed-citation><mixed-citation xml:lang="en">Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116–22. doi:10.1111/j.1600-079X.1995.tb00179.x</mixed-citation></citation-alternatives></ref><ref id="cit128"><label>128</label><citation-alternatives><mixed-citation xml:lang="ru">Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116–22. doi:10.1111/j.1600-079X.1995.tb00179.x</mixed-citation><mixed-citation xml:lang="en">Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116–22. doi:10.1111/j.1600-079X.1995.tb00179.x</mixed-citation></citation-alternatives></ref><ref id="cit129"><label>129</label><citation-alternatives><mixed-citation xml:lang="ru">Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116–22. doi:10.1111/j.1600-079X.1995.tb00179.x</mixed-citation><mixed-citation xml:lang="en">Hajak G, Rodenbeck A, Staedt J, Bandelow B, Huether G, Rüther E. Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res. 1995;19(3):116–22. doi:10.1111/j.1600-079X.1995.tb00179.x</mixed-citation></citation-alternatives></ref><ref id="cit130"><label>130</label><citation-alternatives><mixed-citation xml:lang="ru">Niederhofer H, Staffen W, Mair A, Pittschieler K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Developmental Disorders. 2003;33(4):469–72. doi:10.1023/A:1025027231938</mixed-citation><mixed-citation xml:lang="en">Niederhofer H, Staffen W, Mair A, Pittschieler K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Developmental Disorders. 2003;33(4):469–72. doi:10.1023/A:1025027231938</mixed-citation></citation-alternatives></ref><ref id="cit131"><label>131</label><citation-alternatives><mixed-citation xml:lang="ru">Niederhofer H, Staffen W, Mair A, Pittschieler K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Developmental Disorders. 2003;33(4):469–72. doi:10.1023/A:1025027231938</mixed-citation><mixed-citation xml:lang="en">Niederhofer H, Staffen W, Mair A, Pittschieler K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Developmental Disorders. 2003;33(4):469–72. doi:10.1023/A:1025027231938</mixed-citation></citation-alternatives></ref><ref id="cit132"><label>132</label><citation-alternatives><mixed-citation xml:lang="ru">Niederhofer H, Staffen W, Mair A, Pittschieler K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Developmental Disorders. 2003;33(4):469–72. doi:10.1023/A:1025027231938</mixed-citation><mixed-citation xml:lang="en">Niederhofer H, Staffen W, Mair A, Pittschieler K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Developmental Disorders. 2003;33(4):469–72. doi:10.1023/A:1025027231938</mixed-citation></citation-alternatives></ref><ref id="cit133"><label>133</label><citation-alternatives><mixed-citation xml:lang="ru">Niederhofer H, Staffen W, Mair A, Pittschieler K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Developmental Disorders. 2003;33(4):469–72. doi:10.1023/A:1025027231938</mixed-citation><mixed-citation xml:lang="en">Niederhofer H, Staffen W, Mair A, Pittschieler K. Melatonin facilitates sleep in individuals with mental retardation and insomnia. J Autism Developmental Disorders. 2003;33(4):469–72. doi:10.1023/A:1025027231938</mixed-citation></citation-alternatives></ref><ref id="cit134"><label>134</label><citation-alternatives><mixed-citation xml:lang="ru">Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: A randomised controlled trial. BMC Medicine. 2018;16(1):1–10. doi:10.1186/s12916-017-0995-1</mixed-citation><mixed-citation xml:lang="en">Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: A randomised controlled trial. BMC Medicine. 2018;16(1):1–10. doi:10.1186/s12916-017-0995-1</mixed-citation></citation-alternatives></ref><ref id="cit135"><label>135</label><citation-alternatives><mixed-citation xml:lang="ru">Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: A randomised controlled trial. BMC Medicine. 2018;16(1):1–10. doi:10.1186/s12916-017-0995-1</mixed-citation><mixed-citation xml:lang="en">Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: A randomised controlled trial. BMC Medicine. 2018;16(1):1–10. doi:10.1186/s12916-017-0995-1</mixed-citation></citation-alternatives></ref><ref id="cit136"><label>136</label><citation-alternatives><mixed-citation xml:lang="ru">Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: A randomised controlled trial. BMC Medicine. 2018;16(1):1–10. doi:10.1186/s12916-017-0995-1</mixed-citation><mixed-citation xml:lang="en">Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: A randomised controlled trial. BMC Medicine. 2018;16(1):1–10. doi:10.1186/s12916-017-0995-1</mixed-citation></citation-alternatives></ref><ref id="cit137"><label>137</label><citation-alternatives><mixed-citation xml:lang="ru">Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: A randomised controlled trial. BMC Medicine. 2018;16(1):1–10. doi:10.1186/s12916-017-0995-1</mixed-citation><mixed-citation xml:lang="en">Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: A randomised controlled trial. BMC Medicine. 2018;16(1):1–10. doi:10.1186/s12916-017-0995-1</mixed-citation></citation-alternatives></ref><ref id="cit138"><label>138</label><citation-alternatives><mixed-citation xml:lang="ru">Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion. 2007;23 (10):2597–605. doi:10.1185/030079907X233098</mixed-citation><mixed-citation xml:lang="en">Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion. 2007;23 (10):2597–605. doi:10.1185/030079907X233098</mixed-citation></citation-alternatives></ref><ref id="cit139"><label>139</label><citation-alternatives><mixed-citation xml:lang="ru">Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion. 2007;23 (10):2597–605. doi:10.1185/030079907X233098</mixed-citation><mixed-citation xml:lang="en">Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion. 2007;23 (10):2597–605. doi:10.1185/030079907X233098</mixed-citation></citation-alternatives></ref><ref id="cit140"><label>140</label><citation-alternatives><mixed-citation xml:lang="ru">Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion. 2007;23 (10):2597–605. doi:10.1185/030079907X233098</mixed-citation><mixed-citation xml:lang="en">Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion. 2007;23 (10):2597–605. doi:10.1185/030079907X233098</mixed-citation></citation-alternatives></ref><ref id="cit141"><label>141</label><citation-alternatives><mixed-citation xml:lang="ru">Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion. 2007;23 (10):2597–605. doi:10.1185/030079907X233098</mixed-citation><mixed-citation xml:lang="en">Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55–80 years: quality of sleep and next-day alertness outcomes. Current Medical Research and Opinion. 2007;23 (10):2597–605. doi:10.1185/030079907X233098</mixed-citation></citation-alternatives></ref><ref id="cit142"><label>142</label><citation-alternatives><mixed-citation xml:lang="ru">Van Maanen A, Meijer AM, Smits MG, Van Der Heijden KB, Oort FJ. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017; 40(2):1–11. doi:10.1093/sleep/zsw038</mixed-citation><mixed-citation xml:lang="en">Van Maanen A, Meijer AM, Smits MG, Van Der Heijden KB, Oort FJ. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017; 40(2):1–11. doi:10.1093/sleep/zsw038</mixed-citation></citation-alternatives></ref><ref id="cit143"><label>143</label><citation-alternatives><mixed-citation xml:lang="ru">Van Maanen A, Meijer AM, Smits MG, Van Der Heijden KB, Oort FJ. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017; 40(2):1–11. doi:10.1093/sleep/zsw038</mixed-citation><mixed-citation xml:lang="en">Van Maanen A, Meijer AM, Smits MG, Van Der Heijden KB, Oort FJ. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017; 40(2):1–11. doi:10.1093/sleep/zsw038</mixed-citation></citation-alternatives></ref><ref id="cit144"><label>144</label><citation-alternatives><mixed-citation xml:lang="ru">Van Maanen A, Meijer AM, Smits MG, Van Der Heijden KB, Oort FJ. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017; 40(2):1–11. doi:10.1093/sleep/zsw038</mixed-citation><mixed-citation xml:lang="en">Van Maanen A, Meijer AM, Smits MG, Van Der Heijden KB, Oort FJ. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017; 40(2):1–11. doi:10.1093/sleep/zsw038</mixed-citation></citation-alternatives></ref><ref id="cit145"><label>145</label><citation-alternatives><mixed-citation xml:lang="ru">Van Maanen A, Meijer AM, Smits MG, Van Der Heijden KB, Oort FJ. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017; 40(2):1–11. doi:10.1093/sleep/zsw038</mixed-citation><mixed-citation xml:lang="en">Van Maanen A, Meijer AM, Smits MG, Van Der Heijden KB, Oort FJ. Effects of melatonin and bright light treatment in childhood chronic sleep onset insomnia with late melatonin onset: a randomized controlled study. Sleep. 2017; 40(2):1–11. doi:10.1093/sleep/zsw038</mixed-citation></citation-alternatives></ref><ref id="cit146"><label>146</label><citation-alternatives><mixed-citation xml:lang="ru">Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):307–49. doi:10.5664/jcsm.6506</mixed-citation><mixed-citation xml:lang="en">Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):307–49. doi:10.5664/jcsm.6506</mixed-citation></citation-alternatives></ref><ref id="cit147"><label>147</label><citation-alternatives><mixed-citation xml:lang="ru">Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):307–49. doi:10.5664/jcsm.6506</mixed-citation><mixed-citation xml:lang="en">Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):307–49. doi:10.5664/jcsm.6506</mixed-citation></citation-alternatives></ref><ref id="cit148"><label>148</label><citation-alternatives><mixed-citation xml:lang="ru">Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):307–49. doi:10.5664/jcsm.6506</mixed-citation><mixed-citation xml:lang="en">Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):307–49. doi:10.5664/jcsm.6506</mixed-citation></citation-alternatives></ref><ref id="cit149"><label>149</label><citation-alternatives><mixed-citation xml:lang="ru">Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):307–49. doi:10.5664/jcsm.6506</mixed-citation><mixed-citation xml:lang="en">Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):307–49. doi:10.5664/jcsm.6506</mixed-citation></citation-alternatives></ref><ref id="cit150"><label>150</label><citation-alternatives><mixed-citation xml:lang="ru">Fraer M, Kilic F. Serotonin: a different player in hypertensionassociated thrombosis. Hypertension. 2015;65(5):942–8. doi:10.1161/HYPERTENSIONAHA.114.05061</mixed-citation><mixed-citation xml:lang="en">Fraer M, Kilic F. Serotonin: a different player in hypertensionassociated thrombosis. Hypertension. 2015;65(5):942–8. doi:10.1161/HYPERTENSIONAHA.114.05061</mixed-citation></citation-alternatives></ref><ref id="cit151"><label>151</label><citation-alternatives><mixed-citation xml:lang="ru">Fraer M, Kilic F. Serotonin: a different player in hypertensionassociated thrombosis. Hypertension. 2015;65(5):942–8. doi:10.1161/HYPERTENSIONAHA.114.05061</mixed-citation><mixed-citation xml:lang="en">Fraer M, Kilic F. Serotonin: a different player in hypertensionassociated thrombosis. Hypertension. 2015;65(5):942–8. doi:10.1161/HYPERTENSIONAHA.114.05061</mixed-citation></citation-alternatives></ref><ref id="cit152"><label>152</label><citation-alternatives><mixed-citation xml:lang="ru">Fraer M, Kilic F. Serotonin: a different player in hypertensionassociated thrombosis. Hypertension. 2015;65(5):942–8. doi:10.1161/HYPERTENSIONAHA.114.05061</mixed-citation><mixed-citation xml:lang="en">Fraer M, Kilic F. Serotonin: a different player in hypertensionassociated thrombosis. Hypertension. 2015;65(5):942–8. doi:10.1161/HYPERTENSIONAHA.114.05061</mixed-citation></citation-alternatives></ref><ref id="cit153"><label>153</label><citation-alternatives><mixed-citation xml:lang="ru">Fraer M, Kilic F. Serotonin: a different player in hypertensionassociated thrombosis. Hypertension. 2015;65(5):942–8. doi:10.1161/HYPERTENSIONAHA.114.05061</mixed-citation><mixed-citation xml:lang="en">Fraer M, Kilic F. Serotonin: a different player in hypertensionassociated thrombosis. Hypertension. 2015;65(5):942–8. doi:10.1161/HYPERTENSIONAHA.114.05061</mixed-citation></citation-alternatives></ref><ref id="cit154"><label>154</label><citation-alternatives><mixed-citation xml:lang="ru">Cespuglio R. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. 2018;(49):31–9. doi:10.1016/j.sleep.2018.05.034</mixed-citation><mixed-citation xml:lang="en">Cespuglio R. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. 2018;(49):31–9. doi:10.1016/j.sleep.2018.05.034</mixed-citation></citation-alternatives></ref><ref id="cit155"><label>155</label><citation-alternatives><mixed-citation xml:lang="ru">Cespuglio R. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. 2018;(49):31–9. doi:10.1016/j.sleep.2018.05.034</mixed-citation><mixed-citation xml:lang="en">Cespuglio R. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. 2018;(49):31–9. doi:10.1016/j.sleep.2018.05.034</mixed-citation></citation-alternatives></ref><ref id="cit156"><label>156</label><citation-alternatives><mixed-citation xml:lang="ru">Cespuglio R. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. 2018;(49):31–9. doi:10.1016/j.sleep.2018.05.034</mixed-citation><mixed-citation xml:lang="en">Cespuglio R. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. 2018;(49):31–9. doi:10.1016/j.sleep.2018.05.034</mixed-citation></citation-alternatives></ref><ref id="cit157"><label>157</label><citation-alternatives><mixed-citation xml:lang="ru">Cespuglio R. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. 2018;(49):31–9. doi:10.1016/j.sleep.2018.05.034</mixed-citation><mixed-citation xml:lang="en">Cespuglio R. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. 2018;(49):31–9. doi:10.1016/j.sleep.2018.05.034</mixed-citation></citation-alternatives></ref><ref id="cit158"><label>158</label><citation-alternatives><mixed-citation xml:lang="ru">Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15(4):269–81. doi:10.1016/j.smrv.2010.11.003</mixed-citation><mixed-citation xml:lang="en">Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15(4):269–81. doi:10.1016/j.smrv.2010.11.003</mixed-citation></citation-alternatives></ref><ref id="cit159"><label>159</label><citation-alternatives><mixed-citation xml:lang="ru">Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15(4):269–81. doi:10.1016/j.smrv.2010.11.003</mixed-citation><mixed-citation xml:lang="en">Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15(4):269–81. doi:10.1016/j.smrv.2010.11.003</mixed-citation></citation-alternatives></ref><ref id="cit160"><label>160</label><citation-alternatives><mixed-citation xml:lang="ru">Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15(4):269–81. doi:10.1016/j.smrv.2010.11.003</mixed-citation><mixed-citation xml:lang="en">Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15(4):269–81. doi:10.1016/j.smrv.2010.11.003</mixed-citation></citation-alternatives></ref><ref id="cit161"><label>161</label><citation-alternatives><mixed-citation xml:lang="ru">Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15(4):269–81. doi:10.1016/j.smrv.2010.11.003</mixed-citation><mixed-citation xml:lang="en">Monti JM. Serotonin control of sleep-wake behavior. Sleep Med Rev. 2011;15(4):269–81. doi:10.1016/j.smrv.2010.11.003</mixed-citation></citation-alternatives></ref><ref id="cit162"><label>162</label><citation-alternatives><mixed-citation xml:lang="ru">Murray NM, Buchanan GF, Richerson GB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep. 2015;38 (12):1985–93. doi:10.5665/sleep.5256</mixed-citation><mixed-citation xml:lang="en">Murray NM, Buchanan GF, Richerson GB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep. 2015;38 (12):1985–93. doi:10.5665/sleep.5256</mixed-citation></citation-alternatives></ref><ref id="cit163"><label>163</label><citation-alternatives><mixed-citation xml:lang="ru">Murray NM, Buchanan GF, Richerson GB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep. 2015;38 (12):1985–93. doi:10.5665/sleep.5256</mixed-citation><mixed-citation xml:lang="en">Murray NM, Buchanan GF, Richerson GB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep. 2015;38 (12):1985–93. doi:10.5665/sleep.5256</mixed-citation></citation-alternatives></ref><ref id="cit164"><label>164</label><citation-alternatives><mixed-citation xml:lang="ru">Murray NM, Buchanan GF, Richerson GB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep. 2015;38 (12):1985–93. doi:10.5665/sleep.5256</mixed-citation><mixed-citation xml:lang="en">Murray NM, Buchanan GF, Richerson GB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep. 2015;38 (12):1985–93. doi:10.5665/sleep.5256</mixed-citation></citation-alternatives></ref><ref id="cit165"><label>165</label><citation-alternatives><mixed-citation xml:lang="ru">Murray NM, Buchanan GF, Richerson GB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep. 2015;38 (12):1985–93. doi:10.5665/sleep.5256</mixed-citation><mixed-citation xml:lang="en">Murray NM, Buchanan GF, Richerson GB. Insomnia caused by serotonin depletion is due to hypothermia. Sleep. 2015;38 (12):1985–93. doi:10.5665/sleep.5256</mixed-citation></citation-alternatives></ref><ref id="cit166"><label>166</label><citation-alternatives><mixed-citation xml:lang="ru">Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 2013:62:324–39. doi:10.1016/j.neuint.2012.12.014</mixed-citation><mixed-citation xml:lang="en">Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 2013:62:324–39. doi:10.1016/j.neuint.2012.12.014</mixed-citation></citation-alternatives></ref><ref id="cit167"><label>167</label><citation-alternatives><mixed-citation xml:lang="ru">Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 2013:62:324–39. doi:10.1016/j.neuint.2012.12.014</mixed-citation><mixed-citation xml:lang="en">Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 2013:62:324–39. doi:10.1016/j.neuint.2012.12.014</mixed-citation></citation-alternatives></ref><ref id="cit168"><label>168</label><citation-alternatives><mixed-citation xml:lang="ru">Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 2013:62:324–39. doi:10.1016/j.neuint.2012.12.014</mixed-citation><mixed-citation xml:lang="en">Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 2013:62:324–39. doi:10.1016/j.neuint.2012.12.014</mixed-citation></citation-alternatives></ref><ref id="cit169"><label>169</label><citation-alternatives><mixed-citation xml:lang="ru">Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 2013:62:324–39. doi:10.1016/j.neuint.2012.12.014</mixed-citation><mixed-citation xml:lang="en">Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E et al. Effect of diet on serotonergic neurotransmission in depression. Neurochem Int. 2013:62:324–39. doi:10.1016/j.neuint.2012.12.014</mixed-citation></citation-alternatives></ref><ref id="cit170"><label>170</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin‑1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):1–9. doi:10.1186/s12888-016-1025-0</mixed-citation><mixed-citation xml:lang="en">Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin‑1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):1–9. doi:10.1186/s12888-016-1025-0</mixed-citation></citation-alternatives></ref><ref id="cit171"><label>171</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin‑1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):1–9. doi:10.1186/s12888-016-1025-0</mixed-citation><mixed-citation xml:lang="en">Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin‑1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):1–9. doi:10.1186/s12888-016-1025-0</mixed-citation></citation-alternatives></ref><ref id="cit172"><label>172</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin‑1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):1–9. doi:10.1186/s12888-016-1025-0</mixed-citation><mixed-citation xml:lang="en">Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin‑1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):1–9. doi:10.1186/s12888-016-1025-0</mixed-citation></citation-alternatives></ref><ref id="cit173"><label>173</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin‑1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):1–9. doi:10.1186/s12888-016-1025-0</mixed-citation><mixed-citation xml:lang="en">Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin‑1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16(1):1–9. doi:10.1186/s12888-016-1025-0</mixed-citation></citation-alternatives></ref><ref id="cit174"><label>174</label><citation-alternatives><mixed-citation xml:lang="ru">Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler HB, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):1–15. doi:10.1371/journal.pone.0143397</mixed-citation><mixed-citation xml:lang="en">Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler HB, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):1–15. doi:10.1371/journal.pone.0143397</mixed-citation></citation-alternatives></ref><ref id="cit175"><label>175</label><citation-alternatives><mixed-citation xml:lang="ru">Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler HB, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):1–15. doi:10.1371/journal.pone.0143397</mixed-citation><mixed-citation xml:lang="en">Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler HB, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):1–15. doi:10.1371/journal.pone.0143397</mixed-citation></citation-alternatives></ref><ref id="cit176"><label>176</label><citation-alternatives><mixed-citation xml:lang="ru">Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler HB, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):1–15. doi:10.1371/journal.pone.0143397</mixed-citation><mixed-citation xml:lang="en">Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler HB, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):1–15. doi:10.1371/journal.pone.0143397</mixed-citation></citation-alternatives></ref><ref id="cit177"><label>177</label><citation-alternatives><mixed-citation xml:lang="ru">Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler HB, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):1–15. doi:10.1371/journal.pone.0143397</mixed-citation><mixed-citation xml:lang="en">Baranyi A, Amouzadeh-Ghadikolai O, Rothenhäusler HB, Theokas S, Robier C, Baranyi M, et al. Nitric oxide-related biological pathways in patients with major depression. PLoS ONE. 2015;10(11):1–15. doi:10.1371/journal.pone.0143397</mixed-citation></citation-alternatives></ref><ref id="cit178"><label>178</label><citation-alternatives><mixed-citation xml:lang="ru">Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–88. doi:10.1124/pr.111.004697</mixed-citation><mixed-citation xml:lang="en">Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–88. doi:10.1124/pr.111.004697</mixed-citation></citation-alternatives></ref><ref id="cit179"><label>179</label><citation-alternatives><mixed-citation xml:lang="ru">Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–88. doi:10.1124/pr.111.004697</mixed-citation><mixed-citation xml:lang="en">Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–88. doi:10.1124/pr.111.004697</mixed-citation></citation-alternatives></ref><ref id="cit180"><label>180</label><citation-alternatives><mixed-citation xml:lang="ru">Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–88. doi:10.1124/pr.111.004697</mixed-citation><mixed-citation xml:lang="en">Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–88. doi:10.1124/pr.111.004697</mixed-citation></citation-alternatives></ref><ref id="cit181"><label>181</label><citation-alternatives><mixed-citation xml:lang="ru">Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–88. doi:10.1124/pr.111.004697</mixed-citation><mixed-citation xml:lang="en">Watts SW, Morrison SF, Davis RP, Barman SM. Serotonin and blood pressure regulation. Pharmacol Rev. 2012;64(2):359–88. doi:10.1124/pr.111.004697</mixed-citation></citation-alternatives></ref><ref id="cit182"><label>182</label><citation-alternatives><mixed-citation xml:lang="ru">Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation [Internet]. Biomed Pharmacother. 2017;90:187–93. doi:10.1016/j.biopha.2017.03.053</mixed-citation><mixed-citation xml:lang="en">Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation [Internet]. Biomed Pharmacother. 2017;90:187–93. doi:10.1016/j.biopha.2017.03.053</mixed-citation></citation-alternatives></ref><ref id="cit183"><label>183</label><citation-alternatives><mixed-citation xml:lang="ru">Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation [Internet]. Biomed Pharmacother. 2017;90:187–93. doi:10.1016/j.biopha.2017.03.053</mixed-citation><mixed-citation xml:lang="en">Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation [Internet]. Biomed Pharmacother. 2017;90:187–93. doi:10.1016/j.biopha.2017.03.053</mixed-citation></citation-alternatives></ref><ref id="cit184"><label>184</label><citation-alternatives><mixed-citation xml:lang="ru">Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation [Internet]. Biomed Pharmacother. 2017;90:187–93. doi:10.1016/j.biopha.2017.03.053</mixed-citation><mixed-citation xml:lang="en">Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation [Internet]. Biomed Pharmacother. 2017;90:187–93. doi:10.1016/j.biopha.2017.03.053</mixed-citation></citation-alternatives></ref><ref id="cit185"><label>185</label><citation-alternatives><mixed-citation xml:lang="ru">Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation [Internet]. Biomed Pharmacother. 2017;90:187–93. doi:10.1016/j.biopha.2017.03.053</mixed-citation><mixed-citation xml:lang="en">Razavi BM, Hosseinzadeh H. A review of the role of orexin system in pain modulation [Internet]. Biomed Pharmacother. 2017;90:187–93. doi:10.1016/j.biopha.2017.03.053</mixed-citation></citation-alternatives></ref><ref id="cit186"><label>186</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Implicating the potential role of orexin in hypertension. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2017;390(7):667–76. doi:10.1007/s00210-017-1378‑z</mixed-citation><mixed-citation xml:lang="en">Rani M, Kumar R, Krishan P. Implicating the potential role of orexin in hypertension. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2017;390(7):667–76. doi:10.1007/s00210-017-1378‑z</mixed-citation></citation-alternatives></ref><ref id="cit187"><label>187</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Implicating the potential role of orexin in hypertension. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2017;390(7):667–76. doi:10.1007/s00210-017-1378‑z</mixed-citation><mixed-citation xml:lang="en">Rani M, Kumar R, Krishan P. Implicating the potential role of orexin in hypertension. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2017;390(7):667–76. doi:10.1007/s00210-017-1378‑z</mixed-citation></citation-alternatives></ref><ref id="cit188"><label>188</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Implicating the potential role of orexin in hypertension. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2017;390(7):667–76. doi:10.1007/s00210-017-1378‑z</mixed-citation><mixed-citation xml:lang="en">Rani M, Kumar R, Krishan P. Implicating the potential role of orexin in hypertension. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2017;390(7):667–76. doi:10.1007/s00210-017-1378‑z</mixed-citation></citation-alternatives></ref><ref id="cit189"><label>189</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Implicating the potential role of orexin in hypertension. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2017;390(7):667–76. doi:10.1007/s00210-017-1378‑z</mixed-citation><mixed-citation xml:lang="en">Rani M, Kumar R, Krishan P. Implicating the potential role of orexin in hypertension. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2017;390(7):667–76. doi:10.1007/s00210-017-1378‑z</mixed-citation></citation-alternatives></ref><ref id="cit190"><label>190</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: evidences &amp; mechanisms. Neuropeptides. 2018;68:1–6. doi:10.1016/j.npep.2018.02.002</mixed-citation><mixed-citation xml:lang="en">Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: evidences &amp; mechanisms. Neuropeptides. 2018;68:1–6. doi:10.1016/j.npep.2018.02.002</mixed-citation></citation-alternatives></ref><ref id="cit191"><label>191</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: evidences &amp; mechanisms. Neuropeptides. 2018;68:1–6. doi:10.1016/j.npep.2018.02.002</mixed-citation><mixed-citation xml:lang="en">Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: evidences &amp; mechanisms. Neuropeptides. 2018;68:1–6. doi:10.1016/j.npep.2018.02.002</mixed-citation></citation-alternatives></ref><ref id="cit192"><label>192</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: evidences &amp; mechanisms. Neuropeptides. 2018;68:1–6. doi:10.1016/j.npep.2018.02.002</mixed-citation><mixed-citation xml:lang="en">Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: evidences &amp; mechanisms. Neuropeptides. 2018;68:1–6. doi:10.1016/j.npep.2018.02.002</mixed-citation></citation-alternatives></ref><ref id="cit193"><label>193</label><citation-alternatives><mixed-citation xml:lang="ru">Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: evidences &amp; mechanisms. Neuropeptides. 2018;68:1–6. doi:10.1016/j.npep.2018.02.002</mixed-citation><mixed-citation xml:lang="en">Rani M, Kumar R, Krishan P. Role of orexins in the central and peripheral regulation of glucose homeostasis: evidences &amp; mechanisms. Neuropeptides. 2018;68:1–6. doi:10.1016/j.npep.2018.02.002</mixed-citation></citation-alternatives></ref><ref id="cit194"><label>194</label><citation-alternatives><mixed-citation xml:lang="ru">Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology. 2013; 4:1–10. doi:10.3389/fendo.2013.00018</mixed-citation><mixed-citation xml:lang="en">Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology. 2013; 4:1–10. doi:10.3389/fendo.2013.00018</mixed-citation></citation-alternatives></ref><ref id="cit195"><label>195</label><citation-alternatives><mixed-citation xml:lang="ru">Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology. 2013; 4:1–10. doi:10.3389/fendo.2013.00018</mixed-citation><mixed-citation xml:lang="en">Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology. 2013; 4:1–10. doi:10.3389/fendo.2013.00018</mixed-citation></citation-alternatives></ref><ref id="cit196"><label>196</label><citation-alternatives><mixed-citation xml:lang="ru">Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology. 2013; 4:1–10. doi:10.3389/fendo.2013.00018</mixed-citation><mixed-citation xml:lang="en">Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology. 2013; 4:1–10. doi:10.3389/fendo.2013.00018</mixed-citation></citation-alternatives></ref><ref id="cit197"><label>197</label><citation-alternatives><mixed-citation xml:lang="ru">Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology. 2013; 4:1–10. doi:10.3389/fendo.2013.00018</mixed-citation><mixed-citation xml:lang="en">Inutsuka A, Yamanaka A. The physiological role of orexin/hypocretin neurons in the regulation of sleep/wakefulness and neuroendocrine functions. Frontiers in Endocrinology. 2013; 4:1–10. doi:10.3389/fendo.2013.00018</mixed-citation></citation-alternatives></ref><ref id="cit198"><label>198</label><citation-alternatives><mixed-citation xml:lang="ru">Silvani A. Orexins and the cardiovascular events of awakening. Temperature. 2017;4(2):128–40. doi:10.1080/23328940.2017.1295128</mixed-citation><mixed-citation xml:lang="en">Silvani A. Orexins and the cardiovascular events of awakening. Temperature. 2017;4(2):128–40. doi:10.1080/23328940.2017.1295128</mixed-citation></citation-alternatives></ref><ref id="cit199"><label>199</label><citation-alternatives><mixed-citation xml:lang="ru">Silvani A. Orexins and the cardiovascular events of awakening. Temperature. 2017;4(2):128–40. doi:10.1080/23328940.2017.1295128</mixed-citation><mixed-citation xml:lang="en">Silvani A. Orexins and the cardiovascular events of awakening. Temperature. 2017;4(2):128–40. doi:10.1080/23328940.2017.1295128</mixed-citation></citation-alternatives></ref><ref id="cit200"><label>200</label><citation-alternatives><mixed-citation xml:lang="ru">Silvani A. Orexins and the cardiovascular events of awakening. Temperature. 2017;4(2):128–40. doi:10.1080/23328940.2017.1295128</mixed-citation><mixed-citation xml:lang="en">Silvani A. Orexins and the cardiovascular events of awakening. Temperature. 2017;4(2):128–40. doi:10.1080/23328940.2017.1295128</mixed-citation></citation-alternatives></ref><ref id="cit201"><label>201</label><citation-alternatives><mixed-citation xml:lang="ru">Silvani A. Orexins and the cardiovascular events of awakening. Temperature. 2017;4(2):128–40. doi:10.1080/23328940.2017.1295128</mixed-citation><mixed-citation xml:lang="en">Silvani A. Orexins and the cardiovascular events of awakening. Temperature. 2017;4(2):128–40. doi:10.1080/23328940.2017.1295128</mixed-citation></citation-alternatives></ref><ref id="cit202"><label>202</label><citation-alternatives><mixed-citation xml:lang="ru">Prober DA, Rihel J, Onah AA, Sung R‑J, Schier AF. Hypocretin/Orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26 (51):13400–10. doi:10.1523/JNEUROSCI.4332–06.2006</mixed-citation><mixed-citation xml:lang="en">Prober DA, Rihel J, Onah AA, Sung R‑J, Schier AF. Hypocretin/Orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26 (51):13400–10. doi:10.1523/JNEUROSCI.4332–06.2006</mixed-citation></citation-alternatives></ref><ref id="cit203"><label>203</label><citation-alternatives><mixed-citation xml:lang="ru">Prober DA, Rihel J, Onah AA, Sung R‑J, Schier AF. Hypocretin/Orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26 (51):13400–10. doi:10.1523/JNEUROSCI.4332–06.2006</mixed-citation><mixed-citation xml:lang="en">Prober DA, Rihel J, Onah AA, Sung R‑J, Schier AF. Hypocretin/Orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26 (51):13400–10. doi:10.1523/JNEUROSCI.4332–06.2006</mixed-citation></citation-alternatives></ref><ref id="cit204"><label>204</label><citation-alternatives><mixed-citation xml:lang="ru">Prober DA, Rihel J, Onah AA, Sung R‑J, Schier AF. Hypocretin/Orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26 (51):13400–10. doi:10.1523/JNEUROSCI.4332–06.2006</mixed-citation><mixed-citation xml:lang="en">Prober DA, Rihel J, Onah AA, Sung R‑J, Schier AF. Hypocretin/Orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26 (51):13400–10. doi:10.1523/JNEUROSCI.4332–06.2006</mixed-citation></citation-alternatives></ref><ref id="cit205"><label>205</label><citation-alternatives><mixed-citation xml:lang="ru">Prober DA, Rihel J, Onah AA, Sung R‑J, Schier AF. Hypocretin/Orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26 (51):13400–10. doi:10.1523/JNEUROSCI.4332–06.2006</mixed-citation><mixed-citation xml:lang="en">Prober DA, Rihel J, Onah AA, Sung R‑J, Schier AF. Hypocretin/Orexin overexpression induces an insomnia-like phenotype in zebrafish. J Neurosci. 2006;26 (51):13400–10. doi:10.1523/JNEUROSCI.4332–06.2006</mixed-citation></citation-alternatives></ref><ref id="cit206"><label>206</label><citation-alternatives><mixed-citation xml:lang="ru">Tang S, Huang W, Lu S, Lu L, Li G, Chen X, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61. doi:10.1016/j.peptides.2016.12.008</mixed-citation><mixed-citation xml:lang="en">Tang S, Huang W, Lu S, Lu L, Li G, Chen X, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61. doi:10.1016/j.peptides.2016.12.008</mixed-citation></citation-alternatives></ref><ref id="cit207"><label>207</label><citation-alternatives><mixed-citation xml:lang="ru">Tang S, Huang W, Lu S, Lu L, Li G, Chen X, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61. doi:10.1016/j.peptides.2016.12.008</mixed-citation><mixed-citation xml:lang="en">Tang S, Huang W, Lu S, Lu L, Li G, Chen X, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61. doi:10.1016/j.peptides.2016.12.008</mixed-citation></citation-alternatives></ref><ref id="cit208"><label>208</label><citation-alternatives><mixed-citation xml:lang="ru">Tang S, Huang W, Lu S, Lu L, Li G, Chen X, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61. doi:10.1016/j.peptides.2016.12.008</mixed-citation><mixed-citation xml:lang="en">Tang S, Huang W, Lu S, Lu L, Li G, Chen X, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61. doi:10.1016/j.peptides.2016.12.008</mixed-citation></citation-alternatives></ref><ref id="cit209"><label>209</label><citation-alternatives><mixed-citation xml:lang="ru">Tang S, Huang W, Lu S, Lu L, Li G, Chen X, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61. doi:10.1016/j.peptides.2016.12.008</mixed-citation><mixed-citation xml:lang="en">Tang S, Huang W, Lu S, Lu L, Li G, Chen X, et al. Increased plasma orexin-A levels in patients with insomnia disorder are not associated with prepro-orexin or orexin receptor gene polymorphisms. Peptides. 2017;88:55–61. doi:10.1016/j.peptides.2016.12.008</mixed-citation></citation-alternatives></ref><ref id="cit210"><label>210</label><citation-alternatives><mixed-citation xml:lang="ru">Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kanna H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277(6):1780–5.</mixed-citation><mixed-citation xml:lang="en">Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kanna H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277(6):1780–5.</mixed-citation></citation-alternatives></ref><ref id="cit211"><label>211</label><citation-alternatives><mixed-citation xml:lang="ru">Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kanna H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277(6):1780–5.</mixed-citation><mixed-citation xml:lang="en">Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kanna H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277(6):1780–5.</mixed-citation></citation-alternatives></ref><ref id="cit212"><label>212</label><citation-alternatives><mixed-citation xml:lang="ru">Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kanna H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277(6):1780–5.</mixed-citation><mixed-citation xml:lang="en">Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kanna H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277(6):1780–5.</mixed-citation></citation-alternatives></ref><ref id="cit213"><label>213</label><citation-alternatives><mixed-citation xml:lang="ru">Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kanna H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277(6):1780–5.</mixed-citation><mixed-citation xml:lang="en">Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kanna H. Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol. 1999;277(6):1780–5.</mixed-citation></citation-alternatives></ref><ref id="cit214"><label>214</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Hindmarch CCT, Nattie EE, Paton JFR. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591(17):4237–48 doi:10.1113/jphysiol.2013.256271</mixed-citation><mixed-citation xml:lang="en">Li A, Hindmarch CCT, Nattie EE, Paton JFR. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591(17):4237–48 doi:10.1113/jphysiol.2013.256271</mixed-citation></citation-alternatives></ref><ref id="cit215"><label>215</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Hindmarch CCT, Nattie EE, Paton JFR. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591(17):4237–48 doi:10.1113/jphysiol.2013.256271</mixed-citation><mixed-citation xml:lang="en">Li A, Hindmarch CCT, Nattie EE, Paton JFR. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591(17):4237–48 doi:10.1113/jphysiol.2013.256271</mixed-citation></citation-alternatives></ref><ref id="cit216"><label>216</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Hindmarch CCT, Nattie EE, Paton JFR. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591(17):4237–48 doi:10.1113/jphysiol.2013.256271</mixed-citation><mixed-citation xml:lang="en">Li A, Hindmarch CCT, Nattie EE, Paton JFR. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591(17):4237–48 doi:10.1113/jphysiol.2013.256271</mixed-citation></citation-alternatives></ref><ref id="cit217"><label>217</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Hindmarch CCT, Nattie EE, Paton JFR. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591(17):4237–48 doi:10.1113/jphysiol.2013.256271</mixed-citation><mixed-citation xml:lang="en">Li A, Hindmarch CCT, Nattie EE, Paton JFR. Antagonism of orexin receptors significantly lowers blood pressure in spontaneously hypertensive rats. J Physiol. 2013;591(17):4237–48 doi:10.1113/jphysiol.2013.256271</mixed-citation></citation-alternatives></ref><ref id="cit218"><label>218</label><citation-alternatives><mixed-citation xml:lang="ru">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation><mixed-citation xml:lang="en">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation></citation-alternatives></ref><ref id="cit219"><label>219</label><citation-alternatives><mixed-citation xml:lang="ru">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation><mixed-citation xml:lang="en">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation></citation-alternatives></ref><ref id="cit220"><label>220</label><citation-alternatives><mixed-citation xml:lang="ru">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation><mixed-citation xml:lang="en">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation></citation-alternatives></ref><ref id="cit221"><label>221</label><citation-alternatives><mixed-citation xml:lang="ru">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation><mixed-citation xml:lang="en">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation></citation-alternatives></ref><ref id="cit222"><label>222</label><citation-alternatives><mixed-citation xml:lang="ru">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation><mixed-citation xml:lang="en">Clifford L, Dampney BW, Carrive P. Spontaneously hypertensive rats have more orexin neurons in their medial hypothalamus than normotensive rats. Exp Physiol. 2015;100(4):388–98. doi:10.1113/expphysiol.2014.084137</mixed-citation></citation-alternatives></ref><ref id="cit223"><label>223</label><citation-alternatives><mixed-citation xml:lang="ru">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation><mixed-citation xml:lang="en">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation></citation-alternatives></ref><ref id="cit224"><label>224</label><citation-alternatives><mixed-citation xml:lang="ru">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation><mixed-citation xml:lang="en">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation></citation-alternatives></ref><ref id="cit225"><label>225</label><citation-alternatives><mixed-citation xml:lang="ru">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation><mixed-citation xml:lang="en">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation></citation-alternatives></ref><ref id="cit226"><label>226</label><citation-alternatives><mixed-citation xml:lang="ru">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation><mixed-citation xml:lang="en">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation></citation-alternatives></ref><ref id="cit227"><label>227</label><citation-alternatives><mixed-citation xml:lang="ru">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation><mixed-citation xml:lang="en">Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, Zeitzer JM. Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J App Physiol. 2010;109(4):1053–63. doi:10.1152/japplphysiol.00516.2010</mixed-citation></citation-alternatives></ref><ref id="cit228"><label>228</label><citation-alternatives><mixed-citation xml:lang="ru">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation><mixed-citation xml:lang="en">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation></citation-alternatives></ref><ref id="cit229"><label>229</label><citation-alternatives><mixed-citation xml:lang="ru">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation><mixed-citation xml:lang="en">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation></citation-alternatives></ref><ref id="cit230"><label>230</label><citation-alternatives><mixed-citation xml:lang="ru">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation><mixed-citation xml:lang="en">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation></citation-alternatives></ref><ref id="cit231"><label>231</label><citation-alternatives><mixed-citation xml:lang="ru">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation><mixed-citation xml:lang="en">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation></citation-alternatives></ref><ref id="cit232"><label>232</label><citation-alternatives><mixed-citation xml:lang="ru">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation><mixed-citation xml:lang="en">Berteotti C, Silvani A. The link between narcolepsy and autonomic cardiovascular dysfunction: a translational perspective. Clinical Autonomic Research. 2018;28(6):545–55. doi:10.1007/s10286-017-0473‑z</mixed-citation></citation-alternatives></ref><ref id="cit233"><label>233</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation><mixed-citation xml:lang="en">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation></citation-alternatives></ref><ref id="cit234"><label>234</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation><mixed-citation xml:lang="en">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation></citation-alternatives></ref><ref id="cit235"><label>235</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation><mixed-citation xml:lang="en">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation></citation-alternatives></ref><ref id="cit236"><label>236</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation><mixed-citation xml:lang="en">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation></citation-alternatives></ref><ref id="cit237"><label>237</label><citation-alternatives><mixed-citation xml:lang="ru">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation><mixed-citation xml:lang="en">Li A, Nattie E. Orexin, cardio-respiratory function, and hypertension. Frontiers in Neuroscience. 2014;8:1–18. doi:10.3389/fnins.2014.00022</mixed-citation></citation-alternatives></ref><ref id="cit238"><label>238</label><citation-alternatives><mixed-citation xml:lang="ru">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation><mixed-citation xml:lang="en">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation></citation-alternatives></ref><ref id="cit239"><label>239</label><citation-alternatives><mixed-citation xml:lang="ru">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation><mixed-citation xml:lang="en">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation></citation-alternatives></ref><ref id="cit240"><label>240</label><citation-alternatives><mixed-citation xml:lang="ru">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation><mixed-citation xml:lang="en">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation></citation-alternatives></ref><ref id="cit241"><label>241</label><citation-alternatives><mixed-citation xml:lang="ru">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation><mixed-citation xml:lang="en">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation></citation-alternatives></ref><ref id="cit242"><label>242</label><citation-alternatives><mixed-citation xml:lang="ru">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation><mixed-citation xml:lang="en">Bathgate CJ, Fernandez-Mendoza J. Insomnia, short sleep duration, and high blood pressure: recent evidence and future directions for the prevention and management of hypertension. Curr Hypertens Rep. 2018;20(52):1–9. doi:10.1007/s11906-018-0850-6</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
